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ABSTRACT
Purpose
The purpose of this dissertation was to explore perceptions of social isolation and
social support in individuals with one of two rare lung conditions, alpha-1 antitrypsin
deficiency (AATD) or sarcoidosis. First, a dimensional concept analysis was conducted
to identify key factors contributing to the phenomenon of social isolation. Next, an
integrative review of existing instruments to measure social isolation was conducted to
identify the most appropriate instrument for the study. Finally, a mixed-methods study
was conducted to explore these phenomena in the two populations of interest.
Problem
Many rare diseases are chronic, complex and associated with other disabilities
(M. Anderson, E. Elliott, & Y. Zurynski, 2013). Over the past three decades, social
isolation has been shown to be predictive of mortality and morbidity in both general
populations (Brummett et al., 2001; House, 2001; House, Umberson, & Landis, 1988)
and in populations with chronic conditions (Berkman, 1995; Berkman & Syme, 1979). A
review of the research literature revealed no published studies that explored this
phenomenon in rare disease populations, and specifically, in rare lung diseases (Flavin,
2015a).
The specific aims of the dissertation were:
•

Aim 1: To examine the phenomenon of social isolation through the lens of
dimensional concept analysis
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•

Aim 2: To conduct an integrative review of instruments designed to measure
perceived social isolation

•

Aim 3: To explore the perceptions of social isolation and social support in
individuals with sarcoidosis or alpha-1 antitrypsin deficiency in a pilot study using a
convergent parallel mixed methods design.
Design
A convergent parallel mixed methods study design, informed by social network

theory (Heaney and Israel, 2008) guided the collection of parallel quantitative and
qualitative data streams.
Findings
In the mixed-methods study, there were statistically significant differences in the
Friendship Scale, MOS-SSS emotional support, positive social interaction and total
scores between the alpha-1 and sarcoidosis groups, with higher scores observed in those
with alpha-1 (indicating more social connectedness and perceived support). Sarcoidosisaffected individuals who participated in support groups reported more social isolation as
reflected in the Friendship Scale scores than those who did not participate in support
groups (p=0.04). This was not the case in the AATD population, where access to support
did not significantly alter isolation scores. Content analysis revealed six themes: Selfreflection, building connections, activities, knowledge, relationships and
physical/psychological impact. Triangulation revealed that scores on both instrument
measures were supported by the qualitative data in both groups.

x

Conclusions
Individuals with rare conditions do perceive varying levels of social isolation and
low social support that may not directly correlate with their reported access to support.
The impact of these phenomena is multi-layered and influenced by one’s support
network. These findings merit further exploration in the form of larger studies that
include more geographically and demographically diverse populations. Findings from
this dissertation are significant for nurses and other health care providers because they
allow for a more complete understanding of the issues confronted by individuals and their
family members who are faced with either one of these conditions.
Keywords: social isolation, social support, alpha-1 antitrypsin deficiency,
sarcoidosis, rare disease, mixed-methods
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1.

INTRODUCTION

1.1.

Overview of Dissertation
Many rare diseases are chronic, complex and associated with physical, intellectual

or neurological disabilities (Anderson, Elliott, & Zurynski, 2013). Over the past three
decades, social isolation has been shown to be predictive of mortality and morbidity in
the general population (Brummett et al., 2001; House, 2001; House, Umberson, &
Landis, 1988) and in populations with chronic conditions (Berkman, 1995; Berkman &
Syme, 1979). A review of the research literature revealed no published studies that
explored this phenomenon in rare disease populations, and specifically, in rare lung
diseases (Flavin, 2015a). Despite the high number of individuals affected by rare diseases
as a whole, rare disease patients report often feeling isolated and unable to get the
information and support needed (Colledge & Solly, 2012). This dissertation focused on
investigation of social isolation in a subset of individuals with rare lung diseases,
sarcoidosis and alpha-1 antitrypsin deficiency (AATD).
The specific aims of the dissertation were:
•

Aim 1: To examine the phenomenon of social isolation through the lens of
dimensional concept analysis, identifying the qualities of the concept of social
isolation and exploring the relationships between the qualities in order to define the
essential meanings associated with social isolation

•

Aim 2: To conduct an integrative review of instruments designed to measure
perceived social isolation and examine the qualities of each, in order to choose the
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most appropriate instrument(s) to measure the construct in the populations of
interest.
•

Aim 3: To explore the perceptions of social isolation and social support in
individuals with sarcoidosis or alpha-1 antitrypsin deficiency in a pilot study using a
convergent parallel mixed methods design. We also sought to gain preliminary
understanding of the effects of participation in support groups in these individuals.
The overall objective of this study was to gain insight into perceptions of the

social impact, particularly social isolation and social support, and its consequences as
experienced by individuals with AATD and sarcoidosis. The overarching question
driving this proposal was: To what extent do individuals with the rare lung diseases of
AATD and sarcoidosis perceive the social impact and consequences of living with these
diseases as documented via participant self-report and as measured by the Friendship
Scale and the Medical Outcomes Study – Social Support Survey (MOS-SSS)? The results
of this study provide a framework to design future larger studies that could be used to
validate the findings and ultimately, to develop and test interventions that could
ameliorate these perceptions. The long-term goal of this research trajectory is to refine
hypotheses related to the perceived effect of living with a rare disease on social
interactions and support experienced by individuals with AATD and sarcoidosis and to
inform future intervention development.
2.

BACKGROUND AND PROBLEM STATEMENT
An estimated 10% of Americans live with a diagnosis of one of the 6,000 to 8,000

known rare diseases (Griggs et al., 2009). More specifically, recognition of the
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importance of research into rare lung diseases has been growing (Gupta, Bayoumi, &
Faughnan, 2011). The experience of living with a rare condition is complex and can
significantly affect the individual’s quality of life (Cohen & Biesecker, 2010). Current
clinical practice views the management of rare diseases primarily from the biomedical
approach, seeking to manage clinical physiologic symptoms (Budych, Helms, & Schulz,
2012). Less attention has been given to the psychosocial management of the impact of
these conditions. As these patients may have significant needs and barriers to access to
care (such as geographical distance from an expert provider), alternative interventions to
ameliorate the negative psychosocial aspects of these conditions must be considered. In
rare diseases, there is an increasing importance and presence of the patient as an active
participant in their disease management and decisions (Aujoulat, Young, & Salmon,
2012; Aymé, Kole, & Groft; Black & Baker, 2011; Johnson, Kirschenbaum, Mason, &
Rush, 2005; Polich, 2012). As such, this patient-centric focus calls for a parallel patientcentered research approach, such as interpretive phenomenological analysis (IPA)(Smith,
Michie, Stephenson, & Quarrell, 2002). Before designing interventions, it is prudent to
seek the voice of the patient.
Many studies have adopted a population-based approach to rare diseases, but the
patients’ viewpoint on having such a disorder has remained largely understudied
(Huyard, 2009). These patients can experience a myriad of psychosocial effects,
including social stigma, lack of social support, and perceptions of social isolation. Over
the past decade, social isolation has garnered increased attention as an integral
component of health (World Health Organization, 2002) and the link between social
isolation and health was one focus of the National Research Council’s

(2001) interest
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in integrative health. In a recent review, Cacioppo & Cacioppo (2014) observed the
negative impact that social isolation can have on executive functioning, sleep, and mental
and physical well-being, ultimately resulting in higher rates of morbidity and mortality in
various populations (Cacioppo & Hawkley, 2003; Cacioppo, Hawkley, Norman, &
Berntson, 2011; Cornwell & Waite, 2009; Steptoe, Shankar, Demakakos, & Wardle,
2013). Despite confirmation of perceived social isolation in Internet chat rooms, support
group meetings, and limited studies of rare disease patients (Black & Baker, 2011b;
Coulson, 2005; Coulson, Buchanan, & Aubeeluck, 2007; Lasker, Sogolow, & Sharim,
2005), there is a need for formal study of this phenomenon.
This dissertation is significant because the qualitative component of this study
affords a novel opportunity to gather, firsthand, patient perspectives on the social impact
of rare disease to supplement baseline quantitative data. This mixed methods approach
can be utilized to guide larger studies in more diverse populations of rare disease patients,
with the goal of developing and testing interventions that can enhance social support and
ameliorate the condition of social isolation. This research is also aligned with the
mission of the NINR, and specifically, the need to “develop strategies to assist
individuals and their caregivers in managing chronic illness, including analyses of
caregiver burden and cost-effectiveness” (National Institute of Nursing Research, 2011,
p. 15). This work provides preliminary insights into the experiences of these individuals,
and may serve as a reference point to develop strategies to address the management of the
social isolation component of these rare, chronic diseases. Findings from this study may
also be utilized to explore perceived social isolation and social support in other rare
disease populations.

4

3.

GAPS IN KNOWLEDGE
Few published studies have explored the experiences of living with a rare disease;

no published studies were identified that explored social isolation in rare lung diseases
such as AATD or sarcoidosis. Two studies conducted in the rare disease of scleroderma
identified social isolation as a phenomenon experienced by these individuals. Joachim &
Acorn (2003) conducted a phenomenologic study to investigate the perspective of living
with scleroderma and identified persistent themes of stigma and isolation. In their study
of scleroderma patients, Cinar and colleagues (2012) found similar themes, including
social isolation. Henderson and colleagues (2009) investigated the general psychosocial
impact of living with Niemann Pick disease Type B, a rare lysosomal storage disorder;
they also observed that those patients reported feelings of social isolation. McGarvey and
Hart (2008) surveyed over 200 general practitioners in Ireland; they found that 72% of
GPs agreed that having a rare disorder gives rise to additional family problems and 28%
felt that rare disorders can result in feelings of isolation. No published studies have
focused solely on the phenomenon of perceived social isolation in individuals living with
rare diseases.
Similar results were found when seeking to identify published studies on
perceived social support in these conditions. No published studies were identified that
explored perceived social support in sarcoidosis or AATD, although Hoth and colleagues
(2014) investigated 400 individuals with AATD and found that participation in support
groups was associated with less ambiguity surrounding the disease. A statistically
significant impact on ambiguity was found in those individuals who attended three or
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more support groups in the prior year compared with individuals who reported no such
participation (b=−3.31, SE=1.29, p=0.010)
4.

DESIGN AND METHOD
Both the exploration of the concept of social isolation via dimensional concept

analysis, as well as the integrative review of instruments to measure the concept provided
a framework from which to design the dissertation study. The parallel convergent mixedmethods design of the study was informed by Creswell & Plano Clark (2011). A
quantitative descriptive approach required participants’ completion of the Friendship
Scale (Hawthorne, 2006), a six-item Guttman scale that measures social isolation and the
Medical Outcomes Study: Social Support Survey (MOS-SSS), a 19-item version
instrument that measures perceived availability of social support. Semi-structured,
individual interviews were conducted to describe individuals’ perceptions and
experiences of social support, relationships with others, and preferences for support
strategies. This descriptive approach provided for a comprehensive summary of the
experiences of social isolation and social support in the participants’ own terms
(Sandelowski, 2000). A convergent design facilitated the collection, analysis and
subsequent merging of two independent data streams in a single phase (Creswell & Plano
Clark, 2011). After merging, divergence, convergence and other relationships were
explored.
5.

KEY CONCEPTS/TERMS AND DEFINITIONS
There are two main concepts explored in this dissertation that merit presentation

as a component of the dissertation introduction, social isolation and social support.
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5.1.

Social Isolation
There have been many attempts to operationalize a working definition of social

isolation. The concept of social isolation was first discussed at length in the literature in
the 1970s and 1980s. Despite this rather lengthy history, social isolation continues to be
defined inconsistently and/or used as an adjective describing very low levels of social
support, or limited or lacking social networks (Nicholson, 2009). Warren (1993) offered
four criteria as defining characteristics of the phenomena. The first, stigmatized
environment, implies that a person has been designated as different from other persons,
they perceive this difference and they are hesitant, unwilling, or do not know how to
participate in social interactions with others. This same characteristic was also noted by
Joachim and Acorn (2003) in their focus group interviews conducted with individuals
suffering from the rare disease of scleroderma. The second criterion is that of societal
indifference, where the person perceives that they are lonely, and they lack enduring or
meaningful relationships with others. The third criterion has to do with personal-societal
disconnection, which implies that society rejects and alienates the stigmatized person by
denying them access to satisfying social situations and interactions. Last is the criterion
of personal powerlessness where the stigmatized person buys into their own perception
that society has rejected them; they feel as if they have no control and others possess all
control.
The results of the dimensional analysis conducted as a component of this
dissertation suggest that there are multiple factors related to the concept of social
isolation. Using Schatzman’s approach, the dimensions of perspective, context,
condition, process and consequences were explored as they relate to this concept. The
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first, perspective, is that of limited or low social networks as well as the lack of personal
relationships and is the central organizing standpoint of individuals experiencing
perceived social isolation. The second component, that of context, suggests that the
condition occurs most often in community-dwelling older adults. The conditions that
often foster social isolation are that of a stigmatized environment as well as the disease
condition. The processes that can affect social isolation are peer counseling, support
groups, enhancement of family networks, or internet-based support (Biordi & Nicholson,
2009; Cudney, Butler, Weinert, & Sullivan, 2002, Holley, 2007; Weinert, Cudney, &
Hill, 2008). These findings are congruous with Nicholson’s (2009) proposed definition
of social isolation which suggests that social isolation is a state in which the individual
lacks a sense of belonging socially, lacks engagement with others, and has a minimal
number of social contacts that are deficient in fulfilling and quality relationships. In his
concept analysis of social isolation in older adults, Nicholson (2009) suggested that
determinants of isolation include “number of contacts, feelings of belonging, fulfilling
relationships, engagement with others, and quality of network members” (p. 1349).
Killeen (1998) defines social isolation using two different perspectives: “Social isolation
with choice is aloneness, while social isolation without choice is loneliness” (p.764).
Based on these theories, the working theoretical definition of social isolation is proposed
as living without companionship, having low levels of social contact, little social support,
feeling separate from others, being an outsider, isolated and suffering loneliness
(Hawthorne, 2006).
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5.2.

Social Support
Attempts at crystallizing a definition of social support in the literature are

abundant, and yet, lack of a consensus definition prevails. One theme, however, is
generally consistent in that the construct has been studied primarily from three
perspectives: network structure, support functions and the nature of relationships. Social
support has been defined and measured in various ways (Broadhead et al.1983,
Schwarzer & Knoll 2007). However, most definitions of social support refer in some
context to Cobb’s seminal publication and resulting definition of social support as “the
individual belief that one is cared for and loved, esteemed and valued, and belongs to a
network of communication and mutual obligations” (Cobb, 1976, p. 300). The chosen
instrument, the MOS-SSS reflects these components by its separation and measurement
of the domains of emotional/informational support, tangible support, affectionate support,
and positive social interaction. Strategies to ameliorate perceptions of social isolation
include various types of social support. The need for the assessment and interventions to
address social support needs of individuals with rare conditions is illustrated by the
European Union Committee of Experts on Rare Diseases (EUCERD) in their
investigation into the social support needs of individuals with rare diseases (EUCERD &
Diseases, 2012). While the goal of this study is not to investigate the effect of
interventions, the assessment of the perceptions of social support is important to consider.
6.

THEORETICAL FRAMEWORK
The social network theory proposed by Heaney and Israel (2008) is one that is

most applicable to this work. The model depicts social networks and social support as
the starting point or initiator of a causal flow toward health outcomes. The depiction of
9

this model provides a succinct illustration of how social support and social networks are
intertwined.

Figure 1: Conceptual Model for the Relationship of Social Networks and Social Support to Health

As suggested by Heaney and Israel (2008, p. 189), an understanding of the impact
of social relationships on health status, health behaviors, and health decision making can
contribute to the design of effective interventions for promoting health. In the case of
rare diseases, community empowerment is evident in the alpha-1 population, and less so
(in an organized fashion) in the sarcoidosis population. As illustrated in Figure 1,
Pathway 1 denotes the direct effect of social networks and social support on health. By
meeting human needs for companionship, a sense of belonging, and reassurance of one’s
worth as a person, supportive ties may enhance well-being and health, regardless of stress
10

levels (Berkman and Glass, 2000). This was also observed in the work of Brummett et al
(2001), Berkman and Syme (1979) and House and colleagues (1988). Pathways 2 and 4
represent the effect of social networks and social support on individual coping resources
and community resources, respectively. Pathway 3 suggests that social networks and
social support may influence the frequency and duration of exposure to stressors.
Pathway 5 reflects the potential effects of social networks and social support on health
behaviors. Through social support and such networks, healthy behaviors, adherence to
prescribed regimens and other health-seeking behaviors can be enhanced. In applying
this to the rare disease populations, it is clear that further study is needed, in order to
draw correlations between specific behaviors and health outcomes, as well as
identification of stressors that may be specific to these groups. It is hoped that the results
of this dissertation can provide a sound foundation and framework from which other
work can flourish.
7.

BRIEF OVERVIEW OF MANUSCRIPTS
The first manuscript of this dissertation presents a dimensional concept analysis

of the phenomenon of social isolation (Flavin, 2015a). A concept analysis guides
dissection and examination of key components of the phenomenon under consideration,
affording a multifaceted lens with which to view the attributes of the construct.
Schatzman’s method of dimensional analysis (1991) is particularly suited to exploration
of social isolation. Dimensional analysis (DA) is a method focused on identifying the
various factors that are involved with a phenomenon (Hobbs, 2009), and can be
particularly useful when evaluating an unclear or potentially ambiguous concept (Kools,
McCarthy, Durham, & Robrecht, 1996). Dimensional analysis offers an approach to the
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understanding of social isolation through its social construction and examination of
differences across perspectives and contexts (Udlis, 2011). Schatzman’s methodology
directed the investigator to explore the dimensions of perspective, context, condition,
process and consequences as they relate to social isolation and categorized according to
best fit. By definition, the central theme of social isolation was the perception of having
limited or low social networks as well a lack of personal relationships. The results of the
concept analysis as a whole are presented in the published manuscript entitled “Social
Isolation and its Applicability to Persons with Sarcoidosis and Alpha-1 Antitrypsin
Deficiency: A Dimensional Concept Analysis” (Flavin, 2015a). The results of the
dimensional analysis provided a more robust understanding of the various components
that contribute to the phenomenon of social isolation.
The second manuscript of this dissertation presents the results of an integrative
review of the various instruments available to measure social isolation. This paper,
entitled “Measurements of social isolation and social support for rare lung disease
patients: An integrative review” (Flavin, 2015b) presented the results of a review of eight
instruments that purported to measure the construct of social isolation. From that review,
the Friendship Scale and the UCLA Loneliness Scale were identified as those instruments
with acceptable psychometrics and that would be suitable for pilot use in the populations
of interest.
The third manuscript of the dissertation presents the results of the pilot study,
which used a mixed-methods approach to explore the perceptions of social isolation and
social support in individuals with sarcoidosis or alpha-1 antitrypsin deficiency.
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Abstract
Objective: This parallel, convergent mixed-methods study aimed to explore the
perceptions of social isolation and social support in individuals living with alpha-1
antitrypsin deficiency or sarcoidosis.
Methods: 244 participants completed a series of online questionnaires, including the
Friendship Scale and the Medical Outcomes Study – SocialSupport Survey (MOS-SSS).
29 individuals participated in qualitative interviews. Logistic regression was conducted
to explore whether any of the clinical or demographic characteristics were predictive of
higher/lower social isolation or social support scores. Qualitative content analysis was
conducted to identify themes. Results of the analyses of the two data sets were
triangulated to provide a rich portrait of social isolation and social support as experienced
by these individuals.
Results: There were significant differences in the Friendship Scale, MOS-SSS emotional
support, positive social interaction and total scores between the alpha-1 and sarcoidosis
groups, with higher scores observed in those with alpha-1 (indicating more social
connectedness and perceived support). Sarcoidosis- affected individuals who participated
in support groups reported more social isolation as reflected in the ranks for Friendship
Scale scores than those who did not participate in support groups (p=0.04). Content
analysis revealed six themes: Self-reflection, building connections, activities,
knowledge, relationships and physical/psychological impact. Triangulation revealed that
scores on both instrument measures were supported by the qualitative data in both
groups.
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Conclusion: Less perceived social isolation and more perceived social support were
reported in the alpha-1 population compared with the sarcoidosis population. Social
isolation can be measured and serves as a target for interventions in rare disease
populations.
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Introduction
In recent years, focus on rare diseases has been increasing. An estimated 30
million Americans live with a diagnosis of one of the 6,000 to 8,000 known rare diseases
[1] and such conditions affect approximately 30 million individuals in the European
Union [2]. Two of these conditions – sarcoidosis and alpha-1 antitrypsin deficiency
(AATD) – most often affect the lungs, although other organ involvement occurs.
Sarcoidosis is a chronic, progressive, multisystem granulomatous disease of
unknown etiology [3] for which there is no known cure. The clinical presentation of
sarcoidosis varies and is dependent upon organ and system involvement. Some
individuals present with no physical symptoms, while others may have severe
breathlessness (those with pulmonary involvement), tumor-like growths on the skin or
face (skin sarcoidosis or lupus pernio), or uveitis (ocular involvement). The incidence
and prevalence of sarcoidosis varies worldwide, although regional variations exist. In the
U.S., sarcoidosis is more common in African Americans, with incidence rates as high as
40 per 100 000/year, compared to Whites with an incidence rates range of 5–11 per 100
000/year [4].
AATD is a rare inherited disorder that causes lung and liver disease due to
mutations in the gene SERPINA1, which codes for alpha-1 antitrypsin (AAT). The
clinical presentation of AATD can vary, and is dependent upon a variety of factors,
including genotype. The genetic deficiency predisposes individuals to early-onset
emphysema, one of the phenotypes of COPD [5], although chronic bronchitis and asthma
can also occur. AATD is a metabolic-genetic disease that, in its classical and most
typical form, is caused by homozygosity for the AAT mutant Z gene. These protease
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inhibitor (PI) “Pi*ZZ” genotypes, occur in 1 in 2000 to 3500 births in North American
and European populations [6]. In the United States, prevalence estimates suggest that
there are between 70,000–100,000 AAT-deficient individuals, although only 10% have
been identified [7].
Rare diseases are often chronic, complex and associated with physical, intellectual
or neurological disabilities that may inhibit participation in life activities, thus creating
risk for isolation [8]. Yet, few published studies have explored the experiences of living
with a rare disease. Studies investigating the perspective of individuals living with
scleroderma identified persistent themes of stigma and isolation [9], although this disease
is characterized by skin disease obvious to others. Henderson et al. [10] investigated the
general psychosocial impact of living with Niemann Pick disease Type B, a rare
lysosomal storage disorder, and observed that those patients reported feelings of social
isolation. A survey of over 200 general practitioners (GP) in Ireland revealed that 28%
perceived that rare disorders can result in feelings of isolation [11]. Whether diseases
that have no obvious outward signs impact feelings of isolation remains unstudied.
Social isolation is defined as "a state in which the individual lacks a sense of
belonging socially, lacks engagement with others, has a minimal number of social
contacts and where the individual is deficient in fulfilling and quality relationships" [12].
Over the past three decades, studies have shown social isolation to be predictive of
mortality and morbidity in the general population [13, 14, 15] and in populations with
chronic conditions [16, 17]. Despite the high number of individuals affected by rare
diseases as a whole, patients with rare disease often report feeling isolated and unable to
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get the information and support needed [18]. To date, no studies have specifically
explored social isolation in rare lung diseases such as AATD or sarcoidosis.
Although recognition of the importance of research into rare lung diseases has
been growing [19], this focus has been primarily from the biomedical perspective, with
less attention given to the psychosocial aspects. To address this gap in rare disease
research, the overall objective of our study was to gain insight into perceptions and
consequences of social isolation and social support as experienced by individuals with
AATD and sarcoidosis. In addition, we sought to gain preliminary understanding of the
effects of participation in support groups in these individuals. The overarching question
driving this mixed methods study was: How do individuals with the rare lung diseases of
AATD and sarcoidosis perceive and describe the social impact and consequences of
living with these diseases?
Methods
Design
We applied a parallel convergent mixed-methods design to explore perceptions of
the social impact of living with one of two rare diseases. This design facilitated the
collection and analysis of two independent data streams, one quantitative and one
qualitative, simultaneously with subsequent comparison and merging of findings to
develop a more complete understanding of the social impact of rare lung disease [20].
Participants
Our goal was to recruit an equal distribution of AATD and sarcoidosis
participants. Individuals with AATD were recruited through the Alpha-1 Foundation
Research Registry using an email sent by the registry coordinator. Sarcoidosis
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participants were recruited through snowball sampling beginning with individual
participants of a sarcoidosis support group familiar to the PI. To be eligible, individuals
were required to be adults who self-reported a physician diagnosis of AATD or
sarcoidosis with pulmonary involvement, and confirmed their ability to read and speak
English. There was no specific timeframe required for diagnosis. Individuals were
required to have access to a computer with a valid email address (for purposes of
completing instruments via the Research Electronic Data Capture REDCap survey site).
Data Collection
Participants completed online surveys of validated measures of social isolation
and social support through using (REDCap), an electronic web-based data collection
system [21]. We randomly selected a subgroup of participants who consented to take
part in subsequent qualitative interviews to obtain rich data on perceptions of social
support and relationships with others. A qualitative descriptive approach guided the
interviews to gain a description of social isolation and associated consequences in
everyday terms from the participants [22].
Measures
Demographics and Clinical Characteristics. We collected general demographic
information as well as years since diagnosis, disease condition (sarcoidosis or AATD),
genotype (AATD), disease severity (sarcoidosis), presence of pain or fatigue, frequency
of leaving the home within the prior week, participation in support or advocacy groups
and participation in outside activities.
Pulmonary status. Due to the pulmonary involvement associated with these diseases, we
sought to quantify the effects of breathlessness on everyday activities. The modified
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Medical Research Council (mMRC) Dyspnea Score was used to assess the severity of
perceived breathlessness on a five-point scale (0-4) [23].
Social Isolation. The Friendship Scale [24] is a six-item Guttman scale that measures
perceived social isolation. The scale assesses both critical aspects of social isolation:
perceived social isolation (3 items) and perceived emotional loneliness (3 items). Scores
for each item range from zero to 4 with a total score ranging from zero to 24. Cutpoints to
classify levels of social isolation range from 0-11 (very socially isolated) to 22-24 (very
or highly socially connected) [24]. The psychometric properties of the scale in the
validation study conducted in older adult populations in various types of settings suggest
excellent internal structures as assessed by structural equation modeling (CFI = 0.99,
RMSEA = 0.02), reliability (Cronbach’s alpha = 0.83), and discrimination when assessed
against two other short social relationship scales [24, 25, 26]. A subsequent validation
study in individuals with low back pain showed similar results [25]. Tests of concurrent
discriminant validity suggest it is sensitive to the known correlates of social isolation
[24].
Social Support. We evaluated perceived social support using the Medical Outcomes
Study: Social Support Survey (MOS-SSS). The scale is a 19-item instrument containing
four domains to assess perceived availability of social support, including (1) emotional/
informational support, (2) tangible support, (3) positive social interaction and (4)
affectionate support [27]. Responses are scored via a 5-point Likert-type scale, and range
from “none of the time” to “all of the time”. Scores range from 0-100 with higher scores
indicating more perceived support. Sound psychometrics of the MOS-SSS were
established in the original validation study by Sherbourne and Stewart [27], with
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Cronbach’s alpha ranging from 0.91 to 0.97 for the various subscales and high
convergent and discriminant validity of items. Subsequent and supportive validation
studies were also conducted with Chinese [28], Portuguese [29] and Black individuals
[30].
Qualitative Interviews
Interviews took place via telephone. An interview script comprised of eight questions
was used to facilitate approximately 60-90 minutes of dialogue, although modified where
appropriate.
•
•
•
•
•
•
•
•

I’d like to start by having you describe a typical day
Can you tell me a little bit about how having <<alpha-1/sarcoidosis>> has affected your
life? What place does it have in your life?
How have people in your life reacted to your having <<alpha-1/sarcoidosis>>?
Can you tell me a little bit about how having <<alpha-1/sarcoidosis>> has affected your
relationships with other people?
Can you tell me what happens if you ask others for help?
Tell me a bit how you access support for your condition
What do you do for enjoyment?
Can you tell me a little bit about why you chose to participate in this study?

Semi-structured questions and prompts were used to yield narratives centering on social isolation
and/or social support. All interviews were audio recorded and transcribed.

Statistical and qualitative analysis
During the quantitative data analysis, data were exported from the REDCap
database to SPSS v22 [31] for analysis. The primary analysis used all available data from
all subjects who attempted completion of the questionnaires. Any respondents missing an
item were excluded only from tests involving that item.
Descriptive statistics were computed on the demographic and clinical
characteristics of the study population. For categorical and ordinal variables frequencies
were calculated and reported. For continuous variables, measures of central tendency
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including mean, median and standard deviation were calculated. All continuous variables
were assessed for normality and all distributions of variables were skewed except age;
therefore, appropriate non-parametric analysis methods were used. For age, the two
groups were compared using the independent samples t-test; other continuous variables
were compared using the Mann-Whitney U-test.
Mean total scores (with 95% CIs) and median scores were calculated for the
pooled study population and individual disease groups, for both the Friendship Scale and
MOS-SSS. The average Friendship Scale and MOS-SSS scores are broken down by
condition in the table below and the ranks compared using the Mann-Whitney-U test
(Wilcoxon rank-sum test). To assess the effect of support group participation, the pooled
study population was dichotomized into individuals who reported participating in online
or face-to-face support groups and those who reported not participating in such groups.
Non-parametric Mann-Whitney test was utilized to compare the two groups.
Logistic regression was conducted to explore whether any of the demographic or
clinical characteristics might be predictive of higher/lower social isolation or social
support scores. The Friendship scale was dichotomized into those who were very
isolated, isolated, and with some isolation [range of scores 0-18] versus the socially
connected and very socially connected (range of scores 19-24)[25]. The MOS-SSS was
dichotomized to indicate those who perceived low-normal social support (below 75th
percentile; scores ≤ 85.5) or high social support (above or equal to the 75th percentile;
scores >85.5) [32]. Predictor variables were entered individually, and the individual
effects on the dependent variable(s) of isolation or social support were compared.
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Qualitative analyses of interview data were conducted using NVivo10 qualitative
software [33] and directed content analysis [34, 22]. Each interview was transcribed
after the completion of the interview and the transcript was reviewed in conjunction with
the audio recording. The investigator read the transcripts and used an initial coding
approach to abstract passages in an exploratory manner. Interview transcripts were coded
line-by-line and themes and subthemes developed [35]. After initial themes were
identified, additional data abstraction occurred, including compression of themes [36] and
review by an expert qualitative nurse scientist for confirmation of themes.
Quantitative and qualitative findings were merged to create a robust preliminary
profile of individuals’ perceptions of social isolation and social support. After merging
the two data streams, divergence, convergence and other relationships were explored
[20].
Ethics approval
Institutional Review Board (IRB) approval was obtained at the Medical
University of South Carolina. The study was approved for a waiver of signed consent
and participants were provided with a Statement of Research upon accessing the online
survey. All data were cleaned of any potentially identifying information to maintain
participant anonymity and confidentiality.
Results
Sample
A total of 244 participants completed the online questionnaire, 177 with AATD
and 67 with sarcoidosis. For the sarcoidosis population, 75 participants were contacted
and enrolled via snowball sampling; 67 completed the questionnaires. For the AATD

59

population, a total of 1125 potential participants were contacted in two separate email
“blasts” by the Alpha-1 Registry coordinator, (562 participants in the first email,
followed by 563 different participants in the second email). Of those, 177 subjects
completed the online questionnaires. The initial goal of an equitable distribution of
AATD and sarcoidosis participants was not achieved due to the limited access to and
response of sarcoidosis patients in comparison with the AATD group, and was likely
skewed due to the access facilitated by the AATD registry coordinator.
For the qualitative phase of the study, subjects responded to a single question at
the end of the online questionnaire indicating their willingness to participate in an
interview. Eighty four percent (205/244) of the subjects who participated in the
questionnaire completion agreed to participate in the interviews; of those, twenty-nine
(15=AATD, 14=sarcoidosis) were randomly selected to complete semi-structured,
individual interviews.
AATD subjects were statistically significantly older (59.4 (SD=11.4) than
sarcoidosis participants (50.1 (SD=8.3), p<0.0001). There were was a significant
difference in the gender make-up of the two populations: there was a larger proportion of
males in the AATD group (37.4%) than in the sarcoidosis group (16.4%), while there was
a smaller proportion of females in the AATD (62.6%) group compared to the sarcoidosis
group (83.6%) (p=0.002).
Overall, the study population was primarily female (n=165, 68.5% of all participants).
Pi*ZZ was the most common genotype for alpha-1 participants (97; 55.7%), followed by
MZ (32; 18.4%). Most sarcoidosis participants did not know the stage of their disease
(39; 60.0%) although 18 subjects confirmed that they had either the more severe Stage 3
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or 4 disease (9, 13.8% for each stage). The majority of subjects in both populations were
married. More subjects in the alpha-1 population (93; 53.4%) lived with a spouse or
partner than in the sarcoidosis population (24; 35.8, %, p=0.003). The vast majority was
white and less than 6% of the population self-reported as Hispanic. Annual household
income ranged from $25,000 to $99,000. Additional details are reported in Table 1.
More alpha-1 individuals participated in face-to-face support groups (26.3% vs. 13.6%,
p=0.04), while more sarcoidosis patients participated in online support groups (87.9% vs.
28.0%, p<0.001).
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Table 1 Demographic and clinical characteristics overall and by disease
Variable

Age, mean (SD)
Gender
Male
Female
Marital status, n(%)
Married
Single
Divorced
Widowed
Partnered
Living situation
Alone
With spouse/life partner
With children
With spouse/life partner & children
With a friend
Other
Race
White
Black or African American
American Indian or Alaska Native
Asian Indian
Other
Annual household income (per year)
<$10,000
$10,000-$24,999
$25,000-$49,999
$50,000-$99,999
$100,000+

Study
population
n=244

Alpha-1
n=177

Sarcoidosis
n=67

p-value

56.6	
  (11.4)	
  

59.4	
  (11.4)	
  

50.1	
  (8.3)	
  

*<0.001	
  

76(31.5)	
  

65(37.4)	
  

11(16.4)	
  

*0.002	
  

165(68.5)	
  

109(62.6)	
  

56(83.6)	
  

	
  

154(64.7)	
  

113(65.7)	
  

41(62.1)	
  

0.31	
  

17(7.1)	
  

12(7.0)	
  

5(7.6)	
  

	
  

43(18.1)	
  
7(2.9)	
  
17(7.1)	
  

27(15.7)	
  
7(4.1)	
  
13(7.6)	
  

16(24.2)	
  
0	
  
4(6.1)	
  

	
  
	
  
	
  

39(16.2)	
  
117(48.5)	
  
16(6.6)	
  

32(18.4)	
  
93(53.4)	
  
7(4.0)	
  

7(10.4)	
  
24(35.8)	
  
9(13.4)	
  

*0.003	
  
	
  
	
  

54(22.4)	
  
5(2.1)	
  
10(4.1)	
  

33(19.0)	
  
2(1.1)	
  
7(4.0)	
  

21(31.3)	
  
3(4.5)	
  
3(4.5)	
  

	
  
	
  
	
  

226(93.0)	
  
11(4.5)	
  
1(0.4)	
  
1(0.4)	
  
4(1.6)	
  

173(98.3)	
  
1(0.6)	
  
0	
  
0	
  
1(0.6)	
  

53(79.1)	
  
10(14.9)	
  
1(1.5)	
  
1(1.5)	
  
3(4.5)	
  

<0.001	
  
	
  
	
  
	
  
	
  

10(6.1)
24(14.7)
42(25.8)
63(38.7)
24(14.7)
	
  
19(10.9)	
  

5(8.6)
10(17.2)
16(27.6)
18(31.0)
9(15.5)
	
  
8(12.3)	
  

0.82

MRC	
  Dyspnea	
  Score,	
  n	
  (%)	
  
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  0	
  

15(6.8)
34(15.4)
58(26.2)
81(36.7)
33(14.9)
	
  
27(11.3)	
  

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  1	
  
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  2	
  
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  3	
  
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  4	
  

82(34.2)	
  
97(40.4)	
  
26(10.8)	
  
8(3.3)	
  

64(36.6)	
  
66(37.7)	
  
20(11.4)	
  
6(3.4)	
  

18(27.7)	
  
31(47.7)	
  
6(9.2)	
  
2(3.1)	
  

Participates	
  in	
  face	
  to	
  face	
  support	
  groups,	
  
n	
  (%)	
  
Participates	
  in	
  online	
  support	
  groups,	
  n	
  
(%)	
  
Participates	
  in	
  advocacy	
  groups	
  

55(22.8)	
  

46(26.3)	
  

9(13.6)	
  

	
  
	
  
	
  
	
  
*0.04	
  

107(44.4)	
  

49(28.0)	
  

58(87.9)	
  

*<0.001	
  

56(23.2)	
  

41(23.3)	
  

15(23.1)	
  

0.97	
  

	
  
0.63	
  

*Statistically significant at the 0.05 level
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Social isolation and social support scores
There were statistically significant differences in the Friendship Scale, MOS-SSS
emotional support positive social interaction domains and MOS-SSS total scores between
the two groups, with higher scores observed in those with alpha-1 (indicating more social
connectedness and perceived support). Although not statistically significant, the other
domain scores of the MOS-SSS (tangible support and affectionate support) were also
slightly higher in the AATD group. A comprehensive overview of scores is provided in
Table 2.
Table 2: Average Friendship Scale and Medical Outcomes Scale – Social Support Survey (MOS-SSS) by Study
Population and Condition

Friendship Scale
MOS-SSS
emotional/
informational
support
MOS-SSS
tangible support
MOS-SSS
positive social
interaction
MOS-SSS
affectionate
support
MOS-SSS
Transformed total

All,
(n=244)
Mean
Median
(95% CI)
(IQR)
16.3
17
(15.5-17.1)
(12-22)

Alpha-1,
(n=177)
Mean
Median
(95% CI))
(IQR)
17.0
18
(16.1-17.9)
(13-22)

Sarcoidosis,
(n=67)
Mean
Median
(95% CI)
(IQR)
14.5
15
(12.9-16.1)
(9-20)

27.3
(26.1-28.4)

29
(21-34)

28.1
(26.8-29.4)

30
(21-35.5)

25.0
(22.9-27.1)

14.2
(13.5-14.8)

16
(10-20)

14.5
(13.7-15.3)

16
(10-20)

11.2
(10.7-11.6)

12
(8-15)

11.5
(11.0-12.0)

11.6
(11.1-12.1)

13
(9-15)

63.8
(60.3-67.3)

68.4
(42.1-85.5)

W

Z

p-value

6682.5

-2.595

*0.009

24
(20-32)

6761.5

-2.427

*0.015

13.3
(11.9-14.6)

14
(8-18.3)

7089.5

-1.821

0.07

12
(9-15)

10.3
(9.3-11.3)

12
(6.5-15)

6740.0

-2.096

*0.04

11.8
(11.2-12.4)

13.5
(9-15)

10.9
(9.9-12.0)

12
(7-15)

6916.5

-1.504

0.13

66.4
(62.4-70.5)

73.7
(47.4-88.2)

56.9
(50.0-63.7)

62.5
(35.2-75.0)

5975.0

-2.481

*0.01

*Statistically significant at the 0.05 level

Support Group participation
As illustrated in Table 3, no differences in ranks were observed for either
instrument scores for the overall population in terms of who had participated in support
groups compared to those who had not participated in support groups. This applied to the
AATD population as well. However, in the sarcoidosis population support group
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participants had lower Friendship Scale scores (and thus, were more isolated) compared
to those who did not participate in support groups (with higher scores indicating more
isolation).
Table 3: Friendship Scale and Medical Outcomes Scale – Social Support Survey (MOS-SSS) by Study
Population and Condition by Access to Support
Accessed support
Mean
Median
(95% CI)
(IQR)
All respondents
Total, N
Friendship Scale
MOS-SSS
Transformed total
Alpha-1
Total, N
Friendship Scale
MOS-SSS
Transformed total
Sarcoidosis
Total, N
Friendship Scale
MOS-SSS
Transformed total

Did not access support
Mean(95%
Median
CI))
(IQR)

W

Z

p-value

134
15.9
(14.8-17.0)
63.0
(58.3-67.6)

17
(11-21.5)
68.4
(41.8-83.2)

108
16.9
(15.7-18.0)
64.9
(59.4-70.4)

18
(13-22)
69.
(43.4-90.8)

15256.5

-1.211

0.22

13930.5

-0.635

0.53

75
17.4
(16.1-18.7)
68.7
(62.8-74.5)

19
(13-22)
75
(52.6-88.6)

100
16.7
(15.5-17.9)
64.7
(59.0-70.5)

17
(13-21.5)
66.4
(43.1-90.1)

8153.5

-0.734

0.46

7319.0

-0.754

0.45

59
13.9
(12.2-15.6)
55.6
(48.3-62.86)

14.4
(9-20)
57.9
(34.2-75.0)

8
18.9
(13.7-24.1)
67.1
(38.7-94.5)

22.5
(13.8-23)
73.7
(43.4-96.1)

1836.5

-2.096

*0.04

1679.5

-1.18

0.24

* Statistically significant at the 0.05 level

Predictors of isolation and support
As illustrated in Table 4 and Table 5 in the Appendix, and using the isolation cut
points described previously, females had twice the odds of males to report perceptions of
social isolation (OR=2.10; p=0.01, 95%CI [1.21, 3.66]), and single and divorced persons
had almost 4 times the odds of married individuals to report isolation (OR=3.66 and 3.72;
p=0.03 and 0.001, 95% CI [1.14, 11.74] and [1.71, 8.08] ,respectively). Individuals who
lived alone were also twice as likely to report feeling isolated (OR=2.30; p=0.03, 95% CI
[1.09, 4.88]). Those with more severe breathlessness, as indicated by the MRC Dyspnea
scale score of 3 or 4 (OR=3.58; p=0.03, 95% CI [1.17, 11.01]), or those with more severe
sarcoidosis staging of Stage 3 or 4 (OR=7.78; p=0.03, 95% CI [1.17, 51.92]) were also
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more likely to report feelings of isolation. Individuals with visual impairments had
higher odds of reporting isolation than those who did not have such sight impairments
(OR=2.99; p=0.04, 95% CI [1.06, 8.38]). Odds of reporting significant isolation were
higher for persons who reported difficulties with activities of daily living such as
concentrating (OR=7.28; p<0.001, 95% CI [3.57, 14.86]), walking up stairs (OR=3.38;
p<0.001, 95% CI[1.97, 5.83]), dressing/bathing (OR=2.73, p<0.001, 95% CI[1.48, 5.01])
or doing errands (OR=3.65; p<0.001, 95% CI [2.04, 6.52]) compared to their
counterparts. Odds of reporting significant isolation were also higher for individuals who
reported pain within the prior 30 days (OR=1.07; p<0.001, 95% CI [1.04-1.10]) or
fatigue within the prior 30 days (OR=1.06; p<0.001, 95% CI [1.04, 1.09]) compared to
their counterparts.
The risk factors for lower social support presented in Table 6 and Table 7
included female sex (OR=2.09; p=0.02, 95%CI [0.94, 1.00]), and living alone (OR=4.51;
p=0.02, 95%CI[1.33, 15.34]). Also, the odds of low social support increased for single
(OR=3.28; p=0.13, 95%CI [0.72, 15.05]), divorced (5.78, p=0.01, 95% CI [1.69, 19.75]),
and widowed participants (OR=2.81; p =0.35, 95%CI [0.33, 24.06]) compared to married
participants. Medical factors associated with lower social support included an MRC
dyspnea scale ≥3 or 4 (OR=3.97; p=0.12, 95%CI [0.69, 22.82]), difficulty concentrating
(OR=2.75; p =0.01, 95% CI [1.26, 6.02]), any pain within the prior 30 days (OR=1.04; p
=0.01, 95% CI [1.07, 10.7]) or fatigue within the prior 30 days (OR=1.06: p<0.001, 95%
CI [1.03, 1.09]).
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Qualitative description of social impact of Rare Disease
After initial coding and compression of codes from the qualitative interviews, six
main themes related to the social impact of the disease emerged: Self-reflection, building
connections, activities, knowledge, relationships, and physical/psychological impact.
Self-reflection
The concept of self-reflection emerged as participants described becoming more
insightful and thoughtful about the effect of having a rare disease on their lives. Six
individuals (20.7%) described engaging in activities that facilitated self-reflection to help
them cope, whether by meditation or verbalizing some form of gratitude as a result of
their condition.
Building connections
All of the participants (n = 29, 100%) described “building connections” with
others. These connections were grouped into subcategories of altruism, volunteering, and
a support network. Often, the introduction to a support network was due to the
participant’s desire for additional information after initial diagnosis, and led to the
individual feeling a connection to the group. Such connections were often formed as a
result of feelings of isolation.
…support is very important; you do feel very isolated with this disease…..There is
not a lot of medical information out there. We certainly kick each other’s brains
a lot; what you want, what you being treated with, how much of it they using, how
you feel, how do you feel afterwards….
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We’re all in this together. No matter what we do, when we do it or how we do it
we can make a contribution, all it takes is little time, effort and caring and baby
steps…we’re making strides and something that we’d only discovered 50 years
ago, which is incredible. When you look at other conditions, I think the Alpha-1
community is so progressive in its thinking and in how it generates information
and enthusiasm to help the little ones that are struggling with this and maybe
we’ll see a cure in their lifetime.
Individuals spoke of their experiences volunteering, participating in various
support group venues, and a sense of altruism as a result of their condition. Six
individuals reported volunteering, and most of these activities were not related to their
disease. Activities included church events, free clinic work and education. Twenty-eight
individuals (96.6%) spoke of their experiences with a support network, (family, friends,
organizations like the Alpha-1 network, or Facebook sites and groups). Some
individuals felt that the online sites were negative, with individuals using the sites to vent
complaints. A sarcoidosis participant reported:
I am in a Facebook group and I told my son I find when I am reading some of
their posts I get really frustrated because they will be asking.. well, have you ever
had this or what do you suggest to take if you have low potassium… It's really a
strange thing because it's constant complaining.
Participants with sarcoidosis also often spoke of face-to-face meetings being
widely geographically dispersed, difficult to attend, and poorly attended. As one
individual stated:
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I tried to occasionally attend a sarcoid support group in Portland but that is 140
miles one way. It’s hard to drive that far. I do belong to Inspire Online (an
online support group community). I post there occasionally. I read there. I have
a group that I met from there. One of them I met face to face. We have a group
of seven of us and we have a little private Facebook group.
Activities
Participants described the impact of rare disease on their ability to engage in
routine activities of daily living, including outside activities as well as household
responsibilities and socialization with others. Twenty-two individuals (75.9%)
verbalized impact of the disease on their activities and/or lifestyle, oftentimes leading to
feelings of isolation due to their inability to actively socialize. Individuals described an
intuitive sense of how to pace themselves, however:
I do have to pace myself, I get very tired. And I never feel good, I never ever feel
good.
Relationships
Nineteen (73.1%) of the participants discussed their experiences with seeking
help, which was often a change in established roles with family or friends. That it, many
moved from the “giver” role to the “recipient” role, in terms of assistance. In general,
many individuals were reluctant to ask for help early in the disease process. As one
participant shared:
I hate asking for help, I really do…My husband is a great help and my kids have
stepped up more and helped and they’re of an age now where they can. 13 and 16
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is definitely old enough to help, but I don’t want to be that person that asks for
help because of any issue.
Descriptions of relationships with children varied, with some individuals sharing
about the positive relationships that they had with their children, despite the disease,
while others voiced concern about the effect that the disease had on their children:
It is really hard for her. She remembers mom being able to do more with other
kids. There is a seven or eight years difference between her and my oldest. She
remembers me being much more active; much more able to go do things.
Married participants spoke abundantly about the role of spousal support:
He and I have researched and done everything we can and we still will do
everything that we can to try to get help for this disease and that’s one thing I'm
very fortunate that I have someone that cares that much and loves to be that
involved with me with it.
Physical/psychological impact
The impact on physical or mental well-being was coded under the umbrella of
physical or psychological impact. In general, reports of physical impact were from those
with sarcoidosis and specific to fatigue or pain. In terms of psychological impact,
acceptance was a strong and recurring theme among many individuals. Participants
frequently reported fear at time of diagnosis.
Individuals spoke of becoming isolated as a result of the disease. Whether they
drew back or others pulled away from them, it was clear that this was a major impact of
the disease:
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I have a couple of them still call; I have some that talk to me on Facebook but for
the most part my friends have gone because I don’t have the common things that
we used to working together. So, I don’t have the friendships that I used to
have…. but for the most part I feel pretty lonely
For some, the isolation was so pronounced that it threatened their very existence:
Mostly there are days that are so lonely and so – just – that I have actually said to
my physician I promise you I cannot live the rest of my life this way and I meant
every ounce of the word.
Merging of Data through Triangulation
This mixed methods study was designed to elicit an understanding of the depth
and breadth of perceptions of social isolation and social support in populations with
sarcoidosis or alpha-1. To achieve this, the two data streams were merged via data
triangulation. The essence of a triangulation approach is the ability to utilize two
methods to conduct independent assessments of the same phenomena [37] and to then
integrate the findings. The integration in this study consisted of combining the narrative
qualitative data with the numeric quantitative data. Although these two sets of analyses
were conducted independently, the intent was that the qualitative data would provide
depth and breadth of understanding to the findings from the quantitative data (Figure 1).
This parallel mixed analysis resulted in a convergence (and in some cases, divergence) of
findings that would not be apparent with a single approach. The figure below illustrates
the process by which this parallel mixed analysis was carried out:
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Figure 1: Process of parallel mixed analysis

Although there was much discussion regarding the physical aspects of the disease,
triangulation focused on exploring the narrative comments and their confirmation with or
contradiction to each subgroup’s mean scores of the Friendship Scale and the MOS-SSS.
Common themes mentioned by multiple participants are listed in the qualitative portion
of the summary table (Table 8). Merged findings are presented with quantitative scores of
the two instruments first, followed by qualitative findings that confirm or contradict the
quantitative scores [20]. This data merging process produced a comprehensive, albeit
somewhat limited (due to the size and nature of the study) understanding of this
population’s perceptions of social isolation and social support.
Results of the triangulation analysis indicated that in general, sarcoidosis
participants perceived lower social support, even though they participated in various
online communities. Alpha-1 patients had higher social support scores, and spoke more
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frequently of family support. Both groups described feeling isolated, and these feelings
were reflected in the quantitative Friendship Scale scores. The sarcoidosis group – which
was more overt in their description of feeling isolated, also had lower Friendship Scale
scores as compared to the alpha-1 group; those differences were statistically significant.
For those participants whose direct quotes are featured in Table 3, individual scores are
provided. In general, when comparing individual scores on the two instruments with
what participants stated qualitatively, there was good alignment, with the exception of
few outlying instances
Discussion
Unlike previous studies of populations with rare diseases, this study explored
similarities and differences between two groups with rare lung diseases. It demonstrates
successful conduct of a study in rare groups using virtual methods, which can be a viable
option for groups that are geographically dispersed, or for the ultra-rare diseases. Using a
mixed methods approach, the study design facilitated the analysis of a large number of
perspectives on the social impact of their disease, both quantitatively as well as allowing
for a more in-depth understanding of these concerns and responses via qualitative
interviews. Due to the robust response of the AATD community in particular, a large
number of participants were enrolled, increasing the power of the study to detect
differences.
Findings that individuals who suffer from rare diseases may experience feelings
of social isolation and perceive a lack of social support are not unexpected. What may
not be apparent using one form of data collection and analysis is that these phenomena
are often multi-layered, and that often, the disease’s effect on functional capacity can

72

spur the vicious cycle of isolation. Although individuals reported feeling supported, it is
also evident that some of that support came from virtual communities (such as Facebook)
with their inherent assets and shortcomings. One obvious asset is accessibility
irrespective of geography. An individual can “speak” to a community without having to
overcome transportation and distance challenges, which can be a hurdle in those with
physical or financial constraints. One liability that has not been discussed at length in the
literature is that in some virtual communities, there may be an underlying sense of
“complaining” or “disease one-upmanship”, as some individuals use the virtual boards to
voice a litany of complaints or compare illness notes. The most important finding in this
study was the fact that despite the seemingly “ease of access” of virtual communities, a
number of individuals felt that the tone of many of the groups was negative, and so they
sought to break off and start their own closed groups.
There were subtle differences between the populations that became apparent
during data analysis. For example, although many of the AATD participants knew their
genotype, the majority of sarcoidosis participants did not know their stage of lung
involvement. This may be due to the fact that in this population, staging is not discussed
as frequently as organ involvement when individuals self-classify. There were more
AATD participants who reported being active in face-to-face support groups than
sarcoidosis participants, and conversely, more sarcoidosis participants who reported
activity in online support groups than AATD individuals. This may be driven in part by
the paucity of live support groups available to sarcoidosis patients, and also due to the
influence and reach of the groups sponsored by the Alpha-1 Foundation.
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The AATD population in this study scored higher on both instruments, indicating
more perceived social support and less isolation. These participants frequently
mentioned the presence and impact of the Alpha-1 Foundation and its organized
communities, whereas there was no mention of sarcoidosis organizational involvement in
this sample of sarcoidosis patients. In addition, as there are approved therapies for alpha1 (Alpha-1 Protease Inhibitor, A1PI), individuals who are managed with this therapy also
are assigned to an Alpha-Net coordinator (who also has the condition) who facilitates
care, and often acts as a de facto support person. Among participants, these coordinators
often took the place of support group(s), and were spoken of very highly during the
interviews. In general, there were few divergent findings. Both groups reported some
measure of social support, and some social isolation; much of the qualitative data were
convergent with the instrument scores.
The implications of these findings suggest that support groups and support
persons can be effective in enhancing the lives of individuals with rare diseases. Future
research should examine the similarities and differences of both live and virtual support
groups, and explore structured and unstructured formats for both populations. A more
structured, facilitated sarcoidosis support group could provide additional data to inform
tailoring of future support groups for both populations and recommendations for
facilitating support groups.
Limitations
There were a number of limitations inherent in the study. All participants were
recruited virtually; the results may not be representative of individuals who tend to be
more mobile, or participate in live support groups. Although the study was conducted
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virtually, the two populations were accessed using different approaches. The AATD
participants were part of the MUSC Alpha-1 registry, and by nature, had already
consented to the idea of participating in research. There was likely some degree of
relationship with the coordinator and/or investigator and so there may have been some
bias in terms of their willingness to participate in this study. The sarcoidosis participants
were contacted via convenience or snowball sampling, and were generally not part of an
established unit, such as the MUSC Alpha-1 Registry. However, by virtue of knowing
an individual who was sharing information about the study, some measure of community
bias could have been present. All participants were located in the U.S., and per the study
protocol, were required to have computer access in order to complete the survey; this
may limit the generalizability of the findings. Limitations related to lack of computer
access cannot be dismissed, and the effects of the digital divide still exist. Kontos and
colleagues [38] found that in the U.S, lower socioeconomic status, older, and male adults
were less likely to engage in a number of eHealth activities compared to their
counterparts. In the U.S., sarcoidosis disproportionately affects African-Americans [39],
who often face other economic challenges. Challenges with enrollment were also noted
in a recent web-based survey of sarcoidosis patients including limited access to the
internet, failure to complete surveys, disengagement from healthcare providers and
concerns about protection of personal information [40].
Although no participants voiced concerns about the instruments chosen to
measure social isolation or social support, and there was very little missing data, the
method of dichotomizing the scales to measure isolation and social support may have
diluted some of the information about the magnitude of isolation in the populations.
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However, as this was a pilot study and we sought to mirror previous approaches using
categorical variables, we chose to follow precedent, rather than revert to using continuous
measures.
Conclusion
This population of individuals with AATD or sarcoidosis reported significant
disease-related concerns, and the majority utilized some form of support group or person.
Often, support-seeking was prompted by the individual seeking information. The use of
virtual communities was a common theme, although many of these communities were
criticized by the very individuals they sought to serve because of the tone of negativity
that occasionally, permeated the discussion threads. It may be that such communities
would benefit from the oversight of a facilitator not unlike the established Alpha-Net
coordinator, although issues and challenges of trust also accompany that potential
solution. The ability to measure patient concerns quantitatively, along with enhancing
that information with subjective comments garnered through interviews may help in
crafting future interventions to facilitate support in these populations, as well as other rare
groups. Future research should further examine the phenomena of social isolation and
social support in larger studies and also include other hypothesized predictors of these
feelings.
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Appendices

(Intended for use as online supplementary material)
As illustrated in Table 4, females had twice the odds of males to report
perceptions of social isolation (OR=2.10; p=0.01, 95%CI [1.21, 3.66]), and single and
divorced persons had almost 4 times (OR=3.66 and 3.72; p=0.03 and 0.001, 95% CI
[1.14, 11.74] and [1.71, 8.08] ,respectively) the odds of married individuals to report
isolation (OR=3.66 and 3.72; p=0.03 and 0.001, 95% CI [1.14, 11.74] and [1.71, 8.08]
,respectively). Individuals who lived alone were also twice as likely to report feeling
isolated (OR=2.30; p=0.03, 95% CI [1.09, 4.88]).

Table 4: Associations between Demographic Characteristics and Perceived
Isolation
Isolated,
n(%)
Age
Gender
Male**
33(43.4)
Female
100(61.7)
Marital Status
Married**
71(47.0)
Single
13(76.5)
Divorced
33(76.7)
Widowed
3(42.9)
Partnered
9(52.9)
Living situation
Not alone**
105(52.5)
Alone
28(71.8)
Annual household income
(per year)
<$10,000**
11(78.6)
$10,000-$24,999
27(79.4)
$25,000-$49,999
38(65.5)
$50,000-$99,999
34(42.5)
$100,000+
14(43.8)
Ethnicity
Hispanic, Latino/a or
7(53.8)
Spanish origin**
Not of Hispanic, Latino/a
124(55.4)
or Spanish origin
Race
White**
123(55.2)
Non-white
9(60.0)
*significant at the 0.05 level; ** reference category

OR

95% CI

Wald

df

p-value

0.96

0.94-0.99

8.37

1

*0.004

1
2.10

6.92

1

*0.01

1.21-3.66

1
3.66
3.72
0.85
1.27

14.66

4

1.14-11.74
1.71-8.08
0.18-3.91
0.46-3.46

*0.01
*0.03
*0.001
0.83
0.64

1
2.30

4.75

1

*0.03

1.09-4.88

1
1.05
0.52
0.20
0.21

19.25

4

0.23-4.83
0.13-2.07
0.05-0.78
0.05-0.91

*0.001
0.95
0.35
*0.02
*0.04

0.01

1

0.72

0.13

1

0.65

1
1.06

0.35-3.26

1
1.22

0.42-3.542
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As illustrated in Table 5, individuals who self-reported more severe
breathlessness, as indicated by the MRC Dyspnea scale score of 3 or 4 (OR=3.58;
p=0.03, 95% CI [1.17, 11.01]), or those with more severe sarcoidosis staging of Stage 3
or 4 (OR=7.78; p=0.03, 95% CI [1.17, 51.92]) were also more likely to report feelings of
isolation.
Individuals with visual impairments (OR=2.99; p=0.04, 95% CI [1.06, 8.38]) had
higher odds of reporting isolation than those who did not have such sight impairments
(OR=2.99; p=0.04, 95% CI [1.06, 8.38]). Odds of reporting significant isolation were
higher for persons who reported difficulties with activities of daily living such as
concentrating (OR=7.28; p<0.001, 95% CI [3.57, 14.86]), walking up stairs (OR=3.38;
p<0.001, 95% CI[1.97, 5.83]), dressing/bathing (OR=2.73, p<0.001, 95% CI[1.48, 5.01])
or doing errands (OR=3.65; p<0.001, 95% CI [2.04, 6.52]) also had higher odds of
reporting significant isolation compared to their counterparts. Odds of reporting
significant isolation were also higher for individuals who reported pain within the prior
30 days (OR=1.07; p<0.001, 95% CI [1.04-1.10]) or fatigue within the prior 30 days
(OR=1.06; p<0.001, 95% CI [1.04, 1.09]) had higher odds of reporting significant
isolation compared to their counterparts.
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Table 5: Associations between Clinical Characteristics and Perceived Isolation
Condition
Alpha-1**
Sarcoidosis
Genotype
ZZ**
SZ
MZ
MS/SS/Other
Severity
Stage 1 or 2**
Stage 3 or 4
MRC Dyspnea Score
0**
1
2
3 or 4
Blind or serious difficulty seeing
No**
Yes
Difficulty concentrating,
remembering or making
decisions,
No**
Yes
Difficulty walking or climbing
stairs
No**
Yes
Difficulty dressing or bathing
No**
Yes
Difficulty doing errands alone
No**
Yes
Number days (in past 30) pain
made usual activities hard
Number days (in past 30) fatigue
made usual activities hard
Number days (in past 7) left
house or apartment
Participates in online support
groups
No**
Yes
Participates in face to face
support groups
No**
Yes
Participates in advocacy groups
No**
Yes
Participates in Groups/activities
participated in outside the home
No**
Yes

Isolated, n(%)

OR

95% CI

Wald

df

p-value

90(52.0)
43(65.2)

1
1.72

0.96-3.10

3.30

1

0.07

49(51.6)
9(50.0)
19(59.4)
6(37.5)

1
0.94
1.37
0.56

0.34-2.57
0.61-3.09
0.19-1.67

2.03

3

0.57
0.90
0.45
0.30

3(37.5)
14(82.4)

1
7.78

1.17-51.92

4.49

1

*0.03

14(51.9)
34(44.4)
54(57.4)
27(79.4)

1
0.74
1.25
3.58

0.31-1.78
0.53-2.96
1.17-11.01

11.16

3

*0.01
0.50
0.61
*0.03

115(53.2)
17(77.3)

1
2.99

1.06-8.38

4.31

1

*0.04

70(42.4)
59(84.3)

1
7.28

3.57-14.86

29.7

1

*<0.001

35(37.6)
98(67.1)

1
3.38

1.97-5.83

19.33

1

*<0.001

83(49.1)
50(72.5)

1
2.73

1.48-5.01

10.45

1

*0.001

68(44.7)
65(75.7)

1
3.65
1.07

2.04-6.52
1.04-1.10

19.17

1

*<0.001

23.6

1

*<0.001

1.06

1.04-1.09

27.12

1

*<0.001

0.92

0.87-0.96

12.03

1

*0.001

71(54.2)
61(57.5)

1
1.15

0.27

1

0.61

0.68-1.92

107(58.8)
25(45.5)

1
0.58

3.01

1

0.08

0.32-1.07

103(56.9)
28(50.0)

1
0.757

0.82

1

0.36

0.42-1.38

55(76.4)
78(46.7)

1
0.271

16.88

1

*<0.001

0.15-0.51

*significant at the 0.05 level; ** reference category
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As illustrated in Table 6, females again had twice the odds of reporting lownormal social support (OR=2.09; p=0.02, 95%CI [0.94, 1.00]). Those who lived alone
had over four times the odds of reporting low to normal social support (OR=4.51; p=0.02,
95%CI[1.33, 15.34]). Also, the odds of low social support increased for being single
(OR=3.28; p=0.13, 95%CI [0.72, 15.05]), being divorced (5.78, p=0.01, 95% CI [1.69,
19.75]), and being widowed participants (OR=2.81; p =0.35, 95%CI [0.33, 24.06])
increased the odds of low social support compared to married participants.

Table 6: Associations between Demographic Characteristics and Social Support
Low-normal
social
support
n(%)
Age
Gender
Male**
Female
Marital Status
Married**
Single
Divorced
Widowed
Partnered
Living situation
Not alone**
Alone
Annual household income
(per year)
<$10,000**
$10,000-$24,999
$25,000-$49,999
$50,000-$99,999
$100,000+
Ethnicity
Hispanic, Latino/a or
Spanish origin**
Not of Hispanic, Latino/a
or Spanish origin
Race
White**
Non-white

OR

95% CI

Wald

df

p-value

0.97

0.94-1.00

4.78

1

*0.03

46(65.7)
120(80.0)

1
2.09

5.15

1

*0.02

1.11-3.94

96(68.1)
14(87.5)
37(92.5)
6(85.7)
9 (69.2%)

1
3.28
5.78
2.81
1.06

10.30

4

0.72-15.05
1.69-19.75
0.33-24.06
0.31-3.61

*0.04
0.13
*0.01
0.35
0.93

133(71.5)
34(91.9)

1
4.51

5.84

1

*0.02

1.33-15.34

10(83.3)
28(90.3)
46(85.2)
49(66.2)
22(68.8)

1
1.87
1.15
0.39
0.44

10.45

4

0.27-12.85
0.21-6.23
0.08-1.93
0.08-2.39

*0.03
0.53
0.87
0.25
0.34

7(63.6)

1

0.73

1

0.39

158(75.2)

1.74

0.49-6.17

155(74.9)
11(73.3)

1
1.12

0.02

1

0.89

0.33-3.55

*significant at the 0.05 level; ** reference category
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As illustrated in Table 7, an MRC Dyspnea score of ≥3 or 4 was associated with
lower social support (OR=3.97; p=0.12, 95%CI [0.69, 22.82]). Those individuals who
reported difficulty concentrating (OR=2.75; p =0.01, 95% CI [1.26, 6.02]), any pain
within the prior 30 days (OR=1.04; p =0.01, 95% CI [1.07, 10.7]) or fatigue within the
prior 30 days (OR=1.06: p<0.001, 95% CI [1.03, 1.09]) also had higher odds of low
social support.
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Table 7: Associations between Clinical Characteristics and Social Support

Condition
Alpha-1**
Sarcoidosis
Genotype
ZZ**
SZ
MZ
MS/SS/Other
Severity
Stage 1 or 2**
Stage 3 or 4
MRC Dyspnea Score
0**
1
2
3 or 4
Family history of condition
No**
Yes
Deaf or serious hearing difficulty
No**
Yes
Blind or serious difficulty seeing
No**
Yes
Difficulty concentrating, remembering or
making decisions
No**
Yes
Difficulty walking or climbing stairs
No**
Yes
Difficulty dressing or bathing
No**
Yes
Difficulty doing errands alone
No**
Yes
Number days (in past 30) pain made usual
activities hard
Number days (in past 30) fatigue made usual
activities hard
Number days (in past 7) left house or
apartment
Participates in online support groups
No**
Yes
Participates in face to face support groups
No**
Yes
Participates in advocacy groups
No**
Yes
Participates in Groups/activities participated
in outside the home
No**
Yes

Low-normal
social support
n(%)

OR

95% CI

Wald

df

p-value

116(72.0)
51(82.3)

1
1.80

0.86-3.76

2.44

1

0.12

65(74.7)
12(80.0)
19(61.3)
10(71.4)

1
1.35
0.54
0.85

0.35-5.25
0.23-1.28
0.24-2.97

2.51

3

0.47
0.66
0.16
0.79

5(71.4)
14(82.4)

1
1.87

0.24-1465

0.35

1

0.55

17(77.3)
53(69.7)
68(73.9)
27(93.1)

1
0.678
0.833
3.97

0.22-2.06
0.28-2.50
0.69-22.82

5.35

3

0.15
0.49
0.75
0.12

63(76.8)
68(69.4)

1
0.68

0.35-1.34

1.24

1

0.27

154(74.8)
13(81.3)

1
1.46

0.40-5.34

0.33

1

0.56

150(73.9)
16(88.9)

1
2.28

0.63-12.71

1.84

1

0.18

106(69.7)
57(86.4)

1
2.75

1.26-6.02

6.40

1

*0.01

60(70.6)
107(78.1)

1
1.49

0.80-2.76

1.58

1

0.21

112(72.7)
55(82.1)

1
1.72

0.84-3.53

2.19

1

0.14

101(70.6)
66(83.5)

1
2.11
1.04

1.05-4.23
1.01-1.07

4.44

1

*0.04

6.02

1

*0.01

1.06

1.03-1.09

13.84

1

*<0.001

0.96

0.91-1.01

2.10

1

0.15

85(70.2)
80(80.8)

1
1.78

3.20

1

0.07

0.95-3.36

128(76.2)
37(71.2)

1
0.77

0.54

1

0.46

0.38-1.55

126(74.6)
39(76.5)

1
1.11

0.08

1

0.78

0.53-2.31

60(88.2)
107(69.0)

1
0.297

8.57

1

*0.003

0.13-0.67

*significant at the 0.05 level; ** reference category
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As illustrated in Table 8, and in general, sarcoidosis patients perceived lower
social support, although this group tended to report participating in online communities.
Few of the sarcoidosis subjects interviewed spoke of participating in live support groups,
and for those that did, the groups were small and sparsely attended. Both groups utilized
Facebook groups, although the usefulness of these groups appeared to be in question.
The AATD participants spoke more often of family support, while the sarcoidosis
participants spoke more of peer support.
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Running Head: Social Isolation and Social Support in Alpha-1 and Sarcoidosis

SUMMARY OF MANUSCRIPTS

Overview of Manuscripts’ Contribution to the Question of Perceived Social
Isolation and Social Support in Individuals with Alpha-1 Antitrypsin Deficiency or
Sarcoidosis
Results of a dimensional concept analysis of social isolation served as a
springboard for the work leading to the dissertation study. Findings from this analysis
revealed that the central theme of having limited or low engagement in social networks is
the defining characteristic of individuals experiencing perceived social isolation. Often,
this phenomenon occurs over time in individuals who live with a chronic illness.
Individuals who exist in a stigmatized environment – perceived or actual – are at risk for
social isolation (Chambers et al., 2015; Warren, 1993). These individuals may benefit
from such interventions as peer-based counseling, live support groups or internet-based
support, and further study of these strategies is warranted. A salient finding from the
concept analysis was that social isolation remains widely defined, and a consensus
definition has not yet been reached. In the rare disease community, having cogent
definitions of the various components of social isolation is critical in order to explore the
phenomena, as having a rare disease can be an isolating experience (Patsos, 2001). Of the
published studies reviewed to support the dimensional analysis, no studies were
conducted in rare disease groups. Following that concept analysis, an integrative review
of existing instruments designed to measure perceived social isolation was conducted,
using concepts aligned with the aspects of social isolation identified in the dimensional
analysis to guide instrument identification. From that review of eight instruments, two
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were identified as suitable candidates to be used in pilot study in rare disease patients.
Ultimately, the six-item Friendship Scale was chosen as the instrument for the
dissertation study.
Since no published studies were identified that explored either perceived social
isolation or social support in AATD or sarcoidosis patients, a convergent parallel mixed
methods design was chosen to address this gap. This approach facilitated quantitative
measurement of the concepts, and also applied a patient-centric approach, whereby the
narratives from qualitative interviews, conducted in a random subset of subjects, were
compared with the perceived social isolation scores and social support scores on the
instruments.
The product of the dissertation was a robust overview and profile of patient
perceptions of social isolation and social support that incorporates both quantitative
scores as well as qualitative perspectives. One finding of note was that despite the
frequent use of the Internet and associated chat rooms, Facebook groups and other social
media, many individuals were dissatisfied with the tone of these groups, and so sought to
remove themselves from larger groups. Occasionally, this was done in numbers, such
that a breakaway subgroup of special interest patients was then formed, often as a private
group. This finding of the use of the Internet for support is supported by the literature
(Patsos, 2001; Schumacher et al., 2014), but the concerns over the negative tones
contributes to the existing knowledge.
Subtle differences between the two populations became apparent during the data
analyses. In this study population, many of the AATD participants knew their genotype,
but the majority of sarcoidosis participants did not know their stage of lung involvement.
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In future studies, it may be prudent to determine the type of caregiver(s) that manage
these patients, and the length of time that participants have been under the current
provider’s care. This could shed some light on the patient-clinician relationship, the
ability of individuals to access specialist clinicians, as well as to the level of knowledge
that the participant possesses. This information would be helpful in order to inform
future interventions. There were more AATD participants who reported being active in
face-to-face support groups than sarcoidosis participants, and conversely, a larger
proportion of sarcoidosis participants who reported activity in online support groups than
AATD individuals. This may be driven in part by the paucity of live support groups
available to sarcoidosis patients, and also due to the influence and reach of the groups
sponsored by the Alpha-1 Foundation.
The AATD population in this study scored higher on both instruments, indicating
more perceived social support and less isolation than the sarcoidosis participants,
although the AATD population still scored “somewhat isolated”. Both groups scored as
perceiving low to normal social support, with the sarcoidosis participants reporting lower
social support than their AATD counterparts. The AATD group frequently mentioned
the presence and impact of the Alpha-1 Foundation and its organized communities, and in
fact, this group as a whole reported more frequent participation in face to face support
groups than the sarcoidosis participants. Of note is the fact that by nature, social isolation
is likely to be difficult to alleviate in traditional one-on-one interventions, as this
phenomenon may be more embedded in varying levels of interpersonal interaction than
other social phenomena or social challenges (Cruwys et al., 2014). For example, although
individual counseling may work, it may be more helpful to address it in both individual
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interventions as well as group settings. One working hypothesis is that due to the
“forced” social interaction afforded by these live groups, individuals obtained more
benefit than those who engaged (usually alone) via their computer, but this study was not
designed to test this hypothesis. Future studies could be designed to assess the magnitude
of involvement with a participant’s respective support group or system, in order to tease
out further insights.
Various predictors of perceived social isolation and social support were identified
in the study. Single and divorced persons and those that lived alone had higher odds of
reporting social isolation, as did females. Those with impaired functional capacity, as
measured by perceived breathlessness, or more severe sarcoidosis (as measured by
staging), were more likely to report feeling isolated. Individuals who reported challenges
with certain activities of daily living such as concentrating, walking up stairs ,
dressing/bathing, doing errands or who reported pain, fatigue or visual impairments also
had higher odds of reporting significant isolation compared to their counterparts reporting
less impairment.
Similar results were noted when exploring predictors of low social support.
Females were twice as likely as their male counterparts to report feelings of low social
support. Individuals who were single, divorced or widowed or lived alone also had higher
odds of reporting low social support than those who were married or lived with someone.
Individuals who experienced high levels of dyspnea had more than twice the odds of
reporting low social support. Individuals who reported difficulty concentrating, pain, or
fatigue had higher odds of reporting perceptions of lower support than their counterparts.
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Limitations of Dissertation Research
Limitations of the research are provided within each manuscript. For the concept
analysis of social isolation, there was little published literature identified regarding the
phenomenon in individuals with chronic lung disease. There were also challenges with
searching for literature on the phenomenon: since the concept remains somewhat open to
interpretation, the term “loneliness” is often used interchangeably with “social isolation”.
The same limitation was found when searching the literature for the integrative review of
instruments. In addition, the psychometrics of the instruments were reported
inconsistently, and this proved to make for a challenge in ensuring equitable
comparisons. In terms of the dissertation study, the populations of interest were accessed
in two different ways. The alpha-1 participants were already part of an existing registry,
and so there may have been some bias in terms of their willingness to participate in this
study. The sarcoidosis participants were generally contacted via convenience or snowball
sampling, and were typically not part of an established unit, such as the MUSC Alpha-1
Registry. Limitations related to lack of computer access cannot be dismissed, and have
been noted in other studies of sarcoidosis patients. In the U.S., sarcoidosis
disproportionately affects African-Americans(Rybicki, Major, Popovich, Maliarik, &
Iannuzzi, 1997), who often face other economic challenges. Specific challenges relating
to the recruiting of these individuals were underscored by Dr. Alicia Gerke in regard to
her survey of sarcoidosis patients (Crouser & Judson, 2015). Limited access to the
internet, failure to complete the surveys, disengagement from healthcare providers and a
related lack of trust, such as concerns about protection of their personal information, were
identified as common deterrents(Crouser & Judson, 2015). All participants were located
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in the U.S., and per the study protocol, were required to have computer access in order to
complete the survey; this may limit the generalizability of the findings.
Lessons Learned
The relative ease of recruiting the proposed sample – both in terms of recruitment
time and numbers –was not anticipated. The role of the existing MUSC Alpha-1 registry
coordinator, who had already established a relationship with the Alpha-1 population,
even if only via email, cannot be understated. This registry coordinator was invaluable in
the initial engagement of the potential study participants from this population. The
investigator had an established relationship with a number of active sarcoidosis patients
who reached out to their own networks, and this snowball sampling approach also
benefitted the study enrollment. The investigator was transparent in disclosing that she
was not diagnosed with either condition, and that this work was to support a doctoral
study and pursuit of an academic credential. This transparency seemed to facilitate open
dialogue between subject and investigator.
Further characterization of the population in terms of functional capacity would
have been helpful in order to consider physical limitations that could affect individuals’
mobility and ability to move about within their communities. The investigator collected
information about genotype (in the case of the Alpha-1 population) or staging (in the case
of the sarcoidosis population), as well as breathlessness via subject self-report on a
dyspnea scale. Future studies would be well-served to collect additional information
such as oxygen use, concomitant medications, and perhaps other comorbidities.
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Importance of theory, model or framework to guide overall findings
Social network theory suggests that there is a positive effect of social networks
and social support on an individual’s coping resources, as well as the community
resources that they are able to access(Heaney & Israel, 2008). Heaney suggested that
social networks and social ties can enhance an individual’s overall health status, facilitate
the gathering of information, and ultimately, contribute to an individual’s ability to
problem-solve (Heaney and Israel, 2008). This illustration of the relationship between
social networks and social support, and an individual’s overall health status was the
overarching hypothesis referenced for the design of this study - individuals who accessed
support would be less likely to perceive isolation or low social support, irrespective of
the type of support that they accessed. An individual’s social network, consisting of
both individual and community resources, was also hypothesized to be linked to the
robustness of one’s connectedness and feelings of support. Our findings are somewhat
contradictory to the model, and suggest that for some individuals (such as the sarcoidosis
population in our study), accessing support is not necessarily associated with less social
isolation and higher social support scores. These findings, however, should be
interpreted with caution, as more information would be needed (such as comorbidities,
concomitant medications, etc) in order to draw causal inferences.
Research Trajectory
Further research in this area is warranted. This dissertation was designed as an
exploratory study and was conducted with a small sample that was limited to a population
the investigator could access with relative ease. Larger studies are needed that explore
more geographically diverse populations, with a broader range of demographics. Future
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studies should also enroll participants from a variety of settings, including live or groundbased clinics and/or support groups, in order to compare similarities and differences.
Future studies should also include measures to further characterize the population, such
as including oxygen and concomitant medication use. An ideal approach would be to
convene a group of stakeholders and harness the power of a community-based
participatory research approach, in order to design studies that not only answer the
research question(s) of interest to the investigator, but also to explore issues that are
important to patients. Findings from such studies could then be used to design
interventional studies of various modalities to lessen the perceptions of social isolation or
increase social support. Future research might also include studies to compare the effects
of face to face groups with virtual groups on perceptions of social isolation and social
support, and/or peer-led groups compared to groups led by a trained facilitator on those
same perceptions.
Contribution of Research to Science and Nursing
Nursing research is sparse on the experience of living with a rare disease
(Wagner, Christensen, & Coleman, 2015), and is even more lacking on the concept of
social isolation in the rare disease population, although recent studies are beginning to
address this gap (Garrino et al., 2015; Hoth et al., 2014; Wienke et al., 2014). This
dissertation contributes to the science of nursing by calling attention to this need, and by
highlighting some of the gaps in the published literature on social isolation and social
support in two rare lung diseases. The findings from this study contribute to current
knowledge by identifying similarities and differences that exist between two similar, yet
distinct populations in terms of not only the perceptions of both of these phenomena, but
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the different ways in which individuals seek support. Findings further suggest that there
is a need to explore the framework from which that support stems, whether via
established organizations such as the Alpha-1 Foundation, or more peer-based support
groups, such as Facebook chat rooms and the like. Finally, this study addressed the
alpha-1 and sarcoidosis populations, isolating issues in these populations.
Although the generalizability of the findings from this exploratory study is
limited, the study design and results are valuable. Depending upon the condition, a rare
disease population can be geographically dispersed. In the case of the ultra-rare diseases,
there may be only a few documented cases. By utilizing the power of the internet,
combined with existing resources such as the MUSC registry coordinator, this study’s
investigators were able to enroll a sample of subjects from across the United States, with
diverse demographics. Although this is a limitation as mentioned previously, this also
provides evidence to support the utility of this approach. No longer are researchers
confined by brick and mortar walls. Indeed, some of the ultra-rare conditions are
utilizing a virtual approach to collect data. Marshall-Smith Syndrome is a condition that
is known to affect approximately fifty people worldwide. A global collaboration using an
online wiki to facilitate data collection and sharing has brought together clinicians and
scientists to harness the power of the group(Shaw et al., 2010). This dissertation study
and other studies, similar to the Shaw study, provide compelling evidence to support such
non-traditional approaches. Establishment of such registries is not new to the alpha-1
community. By 2005, following the recommendation of the World Health Organization,
the Alpha One International Registry included 21 countries on four continents, and is
now the largest α1-antitrypsin deficiency registry in the world, with > 4,000 patients
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(Gupta, Bayoumi, & Faughnan, 2011). The registry has facilitated epidemiologic as well
as interventional studies, and is similar to the MUSC Alpha-1 Registry from which
subjects for this study were recruited. In the future, scientists and other clinicians may
find the virtual approach used by this dissertation study to be useful when considering
how best to collect information from their own populations of interest.
The results of this study may be of particular interest to organizations representing
rare disease groups, especially the results which suggest that an organized framework and
some measure of shepherding by peers or other navigators could prove beneficial to
patients, especially at the initial diagnosis. The use of peer-navigators has been explored
in a variety of conditions, including chronic obstructive pulmonary disease (COPD),
spinal cord injury, and breast cancer (Mollica, Nemeth, Newman, Mueller, & Sterba,
2014; Newman et al., 2014; Thomashow et al.). Registries that maintain large numbers
of patients with a given condition have also shown to be useful in contributing to current
and future studies(Strange et al., 2015). By encouraging the nurse scientists of today to
think “out of the box” in anticipation of tomorrow, future work can truly build on the
efforts of our predecessors.
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ADDITIONAL TABLES OF INTEREST TO SUPPORT DISSERTATION STUDY
Table 1

Demographic Characteristics of Pooled Study Population and By Condition

Age, mean (sd)
Gender, n (%)
Male
Female
Marital status, n (%)
Married
Single
Divorced
Widowed
Partnered
Living situation, n (%)
Alone
With spouse/life partner
With children
With spouse/life partner & children
With a friend
Other
Annual household income (per year)
<$10,000
$10,000-$24,999
$25,000-$49,999
$50,000-$99,999
$100,000+
Ethnicity
Hispanic, Latino/a or Spanish origin
Not of Hispanic, Latino/a or Spanish
origin
Race
White
Black or African American
American Indian or Alaska Native
Asian Indian
Other
Prefer not to say

All,
(n=244)
56.6 (11.4)

Alpha-1,
(n=177)
59.4 (11.4)

Sarcoidosis,
(n=67)
50.1 (8.3)

p-value

76(31.5)
165(68.5)

65(37.4)
109(62.6)

11(16.4)
56(83.6)

0.002

154(64.7)
17(7.1)
43(18.1)
7(2.9)
17(7.1)

113(65.7)
12(7.0)
27(15.7)
7(4.1)
13(7.6)

41(62.1)
5(7.6)
16(24.2)
0
4(6.1)

0.317

39(16.2)
117(48.5)
16(6.6)
54(22.4)
5(2.1)
10(4.1)

32(18.4)
93(53.4)
7(4.0)
33(19.0)
2(1.1)
7(4.0)

7(10.4)
24(35.8)
9(13.4)
21(31.3)
3(4.5)
3(4.5)

0.003

15(6.8)
34(15.4)
58(26.2)
81(36.7)
33(14.9)

10(6.1)
24(14.7)
42(25.8)
63(38.7)
24(14.7)

5(8.6)
10(17.2)
16(27.6)
18(31.0)
9(15.5)

0.829

14(5.8)
228(94.2)

8(4.5)
168(95.5)

6(9.1)
60(89.6)

0.216

226(93.0)
11(4.5)
1(0.4)
1(0.4)
4(1.6)
1 (0.4)

173(98.3)
1(0.6)
0
0
1(0.6)
1 (0.6)

53(79.1)
10(14.9)
1(1.5)
1(1.5)
3(4.5)
0

<0.001

<0.001
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Table 2

Clinical Characteristics: Pooled Study Population and By Condition
All,
(n=244)

Genotype (alpha-1), n(%)
ZZ
SZ
SS
MZ
MS
Other
I don’t know
Severity (sarcoidosis), n(%)
Stage 1
Stage 2
Stage 3
Stage 4
I don’t know
MRC Dyspnea Score, n(%)
0
1
2
3
4
MRC Dyspnea Score, median(IQR)
MRC Dyspnea Score, mean (sd)
Number of years with condition,
median(IQR)
Number of years with condition, mean (sd)
Family history of condition, n(%)
Deaf or serious hearing difficulty, n(%)
Blind or serious difficulty seeing, n(%)
Difficulty concentrating, remembering or
making decisions, n(%)
Difficulty walking or climbing stairs, n(%)
Difficulty dressing or bathing, n(%)
Difficulty doing errands alone, n(%)
Number days (in past 30) pain made usual
activities hard, median (IQR)
Number days (in past 30) pain made usual
activities hard, mean (sd)
Number days (in past 30) fatigue made
usual activities hard, median (IQR)
Number days (in past 30) fatigue made
usual activities hard, mean (sd)
Number times (in past 7days) left house or
apartment median (IQR)
Number times (in past 7days) left house or
apartment, mean (sd)
Participates in face to face support groups,
n(%)
Number participated in in past year,
median(IQR)
Number participated in in past year, mean
(sd)
Participates in online support groups, n(%)
Participates in advocacy groups
Groups/activities participated in outside the
home
Church
School/school groups
Sport
Book clubs
Social clubs
Other
None

Alpha-1,
(n=177)

Sarcoidosis,
(n=67)

p-value

97(55.7)
18(10.3)
5(2.9)
32(18.4)
1(0.6)
11(6.3)
10(5.7)
3(4.6)
5(7.7)
9(13.8)
9(13.8)
39(60.0)
27(11.3)
82(34.2)
97(40.4)
26(10.8)
8(3.3)
2(1-2)
1.6(0.9)
7(3-13)

19(10.9)
64(36.6)
66(37.7)
20(11.4)
6(3.4)
2(1-2)
1.6(0.9)
7(3-14)

8(12.3)
18(27.7)
31(47.7)
6(9.2)
2(3.1)
2(1-2)
1.6(0.9)
6(3-12)

0.634

10.0(10.7)
105(53.8)
18(7.4)
23(9.5)
71(29.7)

10.4(11.4)
98(70.0)
12(6.8)
11(6.3)
37(21.5)

8.8(8.7)
7(12.7)
6(9.0)
12(17.9)
34(50.7)

<0.001
0.588
0.006
<0.001

149(61.3)
71(29.3)
88(36.2)
2(0-20)

110(62.5)
55(31.3)
57(32.4)
0(0-10)

39(58.2)
16(24.2)
31(46.3)
18(2-30)

0.539
0.286
0.044
<0.001

9.4(11.9)

6.6(10.4)

16.7(12.8)

15(3-30)

10(2-30)

20(10-30)

15.8(13.9)

14.6(14.7)

18.7(11.2)

5(3-7)

5(3-9)

4(2-7)

6.6(5.8)

7.1(6.2)

5.0(4.4)

55(22.8)

46(26.3)

9(13.6)

0.037

4(2.8-6.0)

4(3-5)

6(1-12)

0.578

4.8(3.7)

4.5(3.3)

6.3(5.2)

107(44.4)
56(23.2)

49(28.0)
41(23.3)

58(87.9)
15(23.1)

<0.001
0.972

73(29.9)
23(9.4)
51(20.9)
11(4.5)
38(17.5)
89(36.5)
75(30.7)

50(28.2)
14(7.9)
45(25.4)
9(5.1)
31(17.5)
70(39.5)
52(29.4)

23(34.3)
9(13.4)
6(9.0)
2(3.0)
7(10.4)
19(28.4)
23(34.3)

0.356
0.188
0.005
0.732
0.175
0.106
0.455

0.657
0.347

0.005

0.012
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Table 3

Ease of Completion of Friendship Scale and MOS-SSS

Friendship Scale*
Very easy to complete
Easy to complete
Hard to complete
Very hard to complete
MOS-SSS**
Very easy to complete
Easy to complete
Hard to complete
Very hard to complete

All
N=244

Alpha-1
N=177

Sarcoidosis
N=64

130(53.9)
86(35.7)
23(9.5)
2(0.8)

97(55.4)
65(37.1)
12(6.9)
1(0.6)

33(50.0)
21(31.8)
11(16.7)
1(1.5)

0.091

129(54.0)
84(35.1)
25(10.5)
1(0.4)

98(56.3)
64(36.8)
12(6.9)
0

31(47.7)
20(30.8)
13(20.0)
1(1.5)

0.009

p-value

109

Table 4

Average Friendship Scale and Medical Outcomes Scale – Social Support Survey (MOSSSS) by Study Population and Condition

Friendship Scale
MOS-SSS
emotional/
informational
support
MOS-SSS tangible
support
MOS-SSS positive
social interaction
MOS-SSS
affectionate
support
MOS-SSS
Transformed total

All,
(n=244)
Mean
Median
(95% CI)
(IQR)
16.3
17
(15.5-17.1)
(12-22)

Alpha-1,
(n=177)
Mean
Median
(95% CI))
(IQR)
17.0
18
(16.1-17.9)
(13-22)

Sarcoidosis,
(n=67)
Mean (95%
Median
CI)
(IQR)
14.5
15
(12.9-16.1)
(9-20)

W

Z

pvalue

6682.5

-2.595

0.009

27.3
(26.1-28.4)

29
(21-34)

28.1
(26.8-29.4)

30
(21-35.5)

25.0
(22.9-27.1)

24
(20-32)

6761.5

-2.427

0.015

14.2
(13.5-14.8)
11.2
(10.7-11.6)

16
(10-20)
12
(8-15)

14.5
(13.7-15.3)
11.5
(11.0-12.0)

16
(10-20)
12
(9-15)

13.3
(11.9-14.6)
10.3
(9.3-11.3)

14
(8-18.3)
12
(6.5-15)

7089.5

-1.821

0.069

6740.0

-2.096

0.036

11.6
(11.1-12.1)

13
(9-15)

11.8
(11.2-12.4)

13.5
(9-15)

10.9
(9.9-12.0)

12
(7-15)

6916.5

-1.504

0.133

63.8
(60.3-67.3)

68.4
(42.185.5)

66.4
(62.4-70.5)

73.7
(47.488.2)

56.9
(50.0-63.7)

62.5
(35.275.0)

5975.0

-2.481

0.013
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Table 5

Friendship Scale and Medical Outcomes Scale – Social Support Survey (MOS-SSS) by
Study Population and Condition by Access to Support

All respondents
Total, N
Friendship Scale
MOS-SSS emotional/
informational support
MOS-SSS tangible
support
MOS-SSS positive
social interaction
MOS-SSS affectionate
support
MOS-SSS
Transformed total
Alpha-1
Total, N
Friendship Scale
MOS-SSS emotional/
informational support
MOS-SSS tangible
support
MOS-SSS positive
social interaction
MOS-SSS affectionate
support
MOS-SSS
Transformed total
Sarcoidosis
Total, N
Friendship Scale
MOS-SSS emotional/
informational support
MOS-SSS tangible
support
MOS-SSS positive
social interaction
MOS-SSS affectionate
support
MOS-SSS
Transformed total

Accessed support
Mean(95%
Median
CI)
(IQR)

Did not access support
Mean(95%
Median
CI))
(IQR)

134
15.9
(14.8-17.0)
26.8
(25.4-28.3)
14.2
(13.3-15.1)
10.9
(10.3-11.6)
11.6
(10.9-12.3)
63.0
(58.3-67.6)

17
(11-21.5)
27
(21-33)
15
(11-19)
12
(8-15)
13
(8.5-15)
68.4
(41.8-83.2)
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16.9
(15.7-18.0)
27.8
(26.0-29.6)
14.2
(13.1-15.3)
11.4
(10.7-12.1)
11.6
(10.9-12.4)
64.9
(59.4-70.4)

75
17.4
(16.1-18.7)
28.6
(26.7-30.5)
15.1
(13.9-16.2)
11.7
(10.9-12.5)
12.2
(11.4-13.1)
68.7
(62.8-74.5)

19
(13-22)
30
(22.5-34.5)
16
(12-20)
12
(9-15)
15
(10-15.0)
75
(52.6-88.6)

14.4
(9-20)
24
(20-30.5)
13.5
(8-18)
11.5
(6-13.5)
12
(7-15)
57.9
(34.2-75.0)

59
13.9
(12.2-15.6)
24.5
(22.3-26.7)
13.1
(11.7-14.4)
10.0
(9.0-11.1)
10.7
(9.5-11.78)
55.6
(48.362.86)

W

Z

p-value

18
(13-22)
30.5
(20-37)
16
(9-20)
12
(9-15)
13
(9-15)
69.
(43.4-90.8)

15256.5

-1.211

0.226

15087.0

-0.958

0.338

15589.5

-0.354

0.723

14922.5

-0.933

0.351

15080.5

-0.157

0.875

13930.5

-0.635

0.526

100
16.7
(15.5-17.9)
27.7
(25.9-29.6)
14.2
(13.0-15.3)
11.4
(10.6-12.1)
11.5
(10.8-12.3)
64.7
(59.0-70.5)

17
(13-21.5)
30.5
(19.8-36.3)
16
(9-20)
12
(9-15)
12
(9-15)
66.4
(43.1-90.1)

8153.5

-0.734

0.463

8270.5

-0.493

0.622

8198.0

-0.877

0.380

7963.0

-1.104

0.270

8004.5

-0.505

0.614

7319.0

-0.754

0.451

8
18.9
(13.7-24.1)
28.6
(19.4-37.8)
14.8
(9.1-20.4)
12.4
(9.5-15.4)
12.9
(10.3-15.5)
67.1
(38.7-94.5)

22.5
(13.8-23)
31
(20-39.3)
17.5
(7.3-20)
12
(12-15)
14
(12-15)
73.7
(43.4-96.1)

1836.5

-2.096

0.036

1888.5

-1.072

0.284

1893.0

0.988

0.323

1759.0

-1.275

0.202

1845.5

-1.476

0.140

1679.5

-1.18

0.238
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Table 6

Logistic Regression Analyses: Association between Demographic Characteristics
and Perceived Social Isolation
Isolated,
n(%)

Age
Gender
Male
Female
Marital Status
Married
Single
Divorced
Widowed
Partnered
Living situation
Not alone
Alone
Annual household income
(per year)
<$10,000
$10,000-$24,999
$25,000-$49,999
$50,000-$99,999
$100,000+
Ethnicity
Hispanic, Latino/a or
Spanish origin
Not of Hispanic, Latino/a
or Spanish origin
Race
White
Non-white

OR

95% CI

Wald

df

p-value

0.96

0.94-0.99

8.37

1

0.004

33(43.4)
100(61.7)

1
2.10

6.92

1

0.009

1.21-3.66

71(47.0)
13(76.5)
33(76.7)
3(42.9)
9(52.9)

1
3.66
3.72
0.85
1.27

14.66

4

0.005

1.14-11.74
1.71-8.08
0.18-3.91
0.46-3.46

105(52.5)
28(71.8)

1
2.30

4.75

1

0.029

1.09-4.88

11(78.6)
27(79.4)
38(65.5)
34(42.5)
14(43.8)

1
1.05
0.52
0.20
0.21

19.25

4

0.001

0.23-4.83
0.13-2.07
0.05-0.78
0.05-0.91

7(53.8)

1

0.01

1

0.715

124(55.4)

1.06

0.35-3.26

123(55.2)
9(60.0)

1
1.22

0.42-3.542

0.13

1

0.653
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Table 7

Logistic Regression Analyses: Associations between Clinical Characteristics and
Perceived Social Isolation

Condition
Alpha-1
Sarcoidosis
Genotype
ZZ
SZ
MZ
MS/SS/Other
Severity
Stage 1 or 2
Stage 3 or 4
MRC Dyspnea Score
0
1
2
3 or 4
Blind or serious difficulty
seeing
No
Yes
Difficulty concentrating,
remembering or making
decisions,
No
Yes
Difficulty walking or
climbing stairs
No
Yes
Difficulty dressing or bathing
No
Yes
Difficulty doing errands alone
No
Yes
Number days (in past 30) pain
made usual activities hard
Number days (in past 30)
fatigue made usual activities
hard
Number days (in past 7) left
house or apartment
Participates in online support
groups
No
Yes
Participates in face to face
support groups
No
Yes
Participates in advocacy
groups
No
Yes
Participates in
Groups/activities participated
in outside the home
No
Yes

Isolated,
n(%)

OR

95% CI

Wald

df

p-value

90(52.0)
43(65.2)

1
1.72

0.96-3.10

3.30

1

0.069

49(51.6)
9(50.0)
19(59.4)
6(37.5)

1
0.94
1.37
0.56

0.34-2.57
0.61-3.09
0.19-1.67

2.03

3

0.567

3(37.5)
14(82.4)

1
7.78

1.17-51.92

4.49

1

0.034

14(51.9)
34(44.4)
54(57.4)
27(79.4)

1
0.74
1.25
3.58

0.31-1.78
0.53-2.96
1.17-11.01

11.16

3

0.010

115(53.2)
17(77.3)

1
2.99

1.06-8.38

4.31

1

0.038

70(42.4)
59(84.3)

1
7.28

3.57-14.86

29.7

1

<0.001

35(37.6)
98(67.1)

1
3.38

1.97-5.83

19.33

1

<0.001

83(49.1)
50(72.5)

1
2.73

1.48-5.01

10.45

1

0.001

68(44.7)
65(75.7)

1
3.65
1.07

2.04-6.52
1.04-1.10

19.17

1

<0.001

23.6

1

<0.001

1.06

1.04-1.09

27.12

1

<0.001

0.92

0.87-0.96

12.03

1

0.001

71(54.2)
61(57.5)

1
1.15

0.27

1

0.606

0.68-1.92

107(58.8)
25(45.5)

1
0.58

3.01

1

0.083

0.32-1.07

103(56.9)
28(50.0)

1
0.757

0.823

1

0.364

0.42-1.38

55(76.4)
78(46.7)

1
0.271

16.88

1

<0.001

0.15-0.51
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Table 8

Logistic Regression Analyses: Associations between Demographic Characteristics
and Social Support
Low-normal
social
support
n(%)

Age
Gender
Male
Female
Marital Status
Married
Single
Divorced
Widowed
Partnered
Living situation
Not alone
Alone
Annual household income
(per year)
<$10,000
$10,000-$24,999
$25,000-$49,999
$50,000-$99,999
$100,000+
Ethnicity
Hispanic, Latino/a or
Spanish origin
Not of Hispanic, Latino/a
or Spanish origin
Race
White
Non-white

OR

95% CI

Wald

df

p-value

0.97

0.94-1.00

4.78

1

0.029

46(65.7)
120(80.0)

1
2.09

5.15

1

0.023

1.11-3.94

96(68.1)
14(87.5)
37(92.5)
6(85.7)
9 (69.2%)

1
3.28
5.78
2.81
1.06

10.30

4

0.036

0.72-15.05
1.69-19.75
0.33-24.06
0.31-3.61

133(71.5)
34(91.9)

1
4.51

5.84

1

0.016

1.33-15.34

10(83.3)
28(90.3)
46(85.2)
49(66.2)
22(68.8)

1
1.87
1.15
0.39
0.44

10.45

4

0.033

0.27-12.85
0.21-6.23
0.08-1.93
0.08-2.39

7(63.6)

1

0.73

1

0.394

158(75.2)

1.74

0.49-6.17

155(74.9)
11(73.3)

1
1.12

0.018

1

0.894

0.33-3.55
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Table 9

Logistic Regression Analyses: Associations between Clinical Characteristics and
Social Support

Condition
Alpha-1
Sarcoidosis
Genotype
ZZ
SZ
MZ
MS/SS/Other
Severity
Stage 1 or 2
Stage 3 or 4
MRC Dyspnea Score
0
1
2
3 or 4
Family history of condition
No
Yes
Deaf or serious hearing difficulty
No
Yes
Blind or serious difficulty seeing
No
Yes
Difficulty concentrating,
remembering or making decisions
No
Yes
Difficulty walking or climbing stairs
No
Yes
Difficulty dressing or bathing
No
Yes
Difficulty doing errands alone
No
Yes
Number days (in past 30) pain made
usual activities hard
Number days (in past 30) fatigue
made usual activities hard
Number days (in past 7) left house or
apartment
Participates in online support groups
No
Yes
Participates in face to face support
groups
No
Yes
Participates in advocacy groups
No
Yes
Participates in Groups/activities
participated in outside the home
No
Yes

Low-normal
social support
n(%)

OR

95% CI

Wald

df

p-value

116(72.0)
51(82.3)

1
1.80

0.86-3.76

2.44

1

0.118

65(74.7)
12(80.0)
19(61.3)
10(71.4)

1
1.35
0.54
0.85

0.35-5.25
0.23-1.28
0.24-2.97

2.51

3

0.473

5(71.4)
14(82.4)

1
1.87

0.24-1465

0.353

1

0.553

17(77.3)
53(69.7)
68(73.9)
27(93.1)

1
0.678
0.833
3.97

0.22-2.06
0.28-2.50
0.69-22.82

5.35

3

0.148

63(76.8)
68(69.4)

1
0.68

0.35-1.34

1.24

1

0.265

154(74.8)
13(81.3)

1
1.46

0.40-5.34

0.33

1

0.564

150(73.9)
16(88.9)

1
2.28

0.63-12.71

1.84

1

0.175

106(69.7)
57(86.4)

1
2.75

1.26-6.02

6.40

1

0.011

60(70.6)
107(78.1)

1
1.49

0.80-2.76

1.58

1

0.209

112(72.7)
55(82.1)

1
1.72

0.84-3.53

2.19

1

0.139

101(70.6)
66(83.5)

1
2.11
1.04

1.05-4.23
1.01-1.07

4.44

1

0.035

6.02

1

0.014

1.06

1.03-1.09

13.84

1

<0.001

0.96

0.91-1.01

2.10

1

0.148

85(70.2)
80(80.8)

1
1.78

3.20

1

0.074

0.95-3.36

128(76.2)
37(71.2)

1
0.77

0.54

1

0.464

0.38-1.55

126(74.6)
39(76.5)

1
1.11

0.08

1

0.782

0.53-2.31

60(88.2)
107(69.0)

1
0.297

8.57

1

0.003

0.13-0.67
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Table 10

Reliability of Friendship Scale and MOS-SSS: By Study Population and Disease
Condition

Friendship scale
MOS-SSS emotional/ informational support
MOS-SSS tangible support
MOS-SSS positive social interaction
MOS-SSS affectionate support
MOS-SSS Transformed total

All
Cronbach’s α

Alpha-1,
Cronbach’s α

Sarcoidosis,
Cronbach’s α

0.915
0.961
0.960
0.961
0.964
0.974

0.912
0.962
0.959
0.964
0.960
0.973

0.920
0.953
0.961
0.959
0.971
0.973
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Table 11

Convergent Validity

MOS-SSS emotional/ informational support
MOS-SSS tangible support
MOS-SSS positive social interaction
MOS-SSS affectionate support
MOS-SSS Transformed total

Correlation with Friendship
Scale, r
0.737
0.598
0.611
0.713
0.760

p-value
<0.001
<0.001
<0.001
<0.001
<0.001
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Appendix A MUSC IRB APPROVAL LETTERS (INITIAL PROTOCOL AND AMENDMENT 1)
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Institutional Review Board for Human Research (IRB)
Office of Research Integrity (ORI)
Medical University of South Carolina
Harborview Office Tower
19 Hagood Ave., Suite 601, MSC857
Charleston, SC 29425-8570
Federal Wide Assurance # 1888
APPROVAL:
This is to certify that the research proposal Pro00039793 entitled:
A Mixed Methods Study of Social Isolation and Social Support in Alpha-1 Antitrypsin Deficiency and
Sarcoidosis
Submitted by: Susan Flavin
Department: Medical University of South Carolina
For consideration has been reviewed by IRB-I - Medical University of South Carolina and approved with
respect to the study of human subjects as adequately protecting the rights and welfare of the individuals
involved, employing adequately methods of securing informed consent from these individuals and not involving
undue risk in the light of potential benefits to be derived therefrom. Additionally, the Institutional Review Board
for Human Research (IRB) recommends approval of the investigator's request for Waiver of Signed Consent in
accordance with 45 CFR 46.117(c)(1),(2) because the only record linking the subject and the research would
be the consent document and the principal risk would be potential harm resulting from a breach of
confidentiality and/or because the research presents no more than minimal risk and involves no procedures for
which written consent is normally required outside of the research context. The Institutional Review Board for
Human Research (IRB) also recommends approval of the investigator's request for a HIPAA Waiver of
Authorization, as it appears that the criteria of the Privacy Rule have been satisfied. The HIPAA Waiver of
Authorization was reviewed under expedited review procedures. No IRB member who has a conflicting interest
was involved in the review or approval of this study, except to provide information as requested by the IRB.
Original Approval Date: 1/28/2015
Approval Expiration: 1/27/2016
Type: Expedited
Chairman, IRB-I - Medical University of South Carolina
Mark Hamner*
Statement of Principal Investigator:
As previously signed and certified, I understand that approval of this research involving human subjects is
contingent upon my agreement:
1. To report to the Institutional Review Board for Human Research (IRB) any adverse events or research
related injuries which might occur in relation to the human research. I have read and will comply with
IRB reporting requirements for adverse events.
2. To submit in writing for prior IRB approval any alterations to the plan of human research.
3. To submit timely continuing review reports of this research as requested by the IRB.
4. To maintain copies of all pertinent information related to the research activities in this project, including
copies of informed consent agreements obtained from all participants.
5. To notify the IRB immediately upon the termination of this project, and/or the departure of the principal
investigator from this Institution and the project.
∗ Electronic Signature: This document has been electronically signed by the IRB Chairman through
the HSSC eIRB Submission System authorizing IRB approval for this study as described in this letter.
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Institutional Review Board for Human Research (IRB)
Office of Research Integrity (ORI)
Medical University of South Carolina
Harborview Office Tower
19 Hagood Ave., Suite 601, MSC857
Charleston, SC 29425-8570
Federal Wide Assurance # 1888
APPROVAL:

Protocol: MS2_Pro00039793
MUSC Amendment # Ame2_Pro00039793
Amendment Title Amendment 2 for IRB Study #Pro00039793

This is to certify that the amendment to the research proposal entitled:
A Mixed Methods Study of Social Isolation and Social Support in Alpha-1 Antitrypsin Deficiency and
Sarcoidosis
and submitted by: Susan Flavin
Department:	
  Medical University of South Carolina
Sponsor: 	
  
for consideration has been reviewed by IRB-I - Medical University of South Carolina and approved with
respect to the study of human subjects as adequately protecting the rights and welfare of individuals involved,
employing adequate methods of securing informed consent from these individuals and not involving undue risk in
the light of potential benefits to be derived therefrom. No IRB member who has a conflicting interest was involved
in the review or approval of this amendment, except to provide information as requested by the IRB. If this
amendment required a change in the currently approved informed consent, then all previous consents should be
marked obsolete.
Approval Date: 4/23/2015
Amendment Type: Expedited
Chair, IRB-I - Medical University of South Carolina
Mark Hamner∗
∗ Electronic Signature: This document has been electronically signed by the IRB Chairman through the HSSC
eIRB Submission System authorizing IRB approval for this study as described in this letter.
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Appendix C IRB-Approved Recruitment Flyer
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Appendix D Letters of Support from NORD and INSPIRE
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Appendix E Letters of Permission from Journal Editors to Use Published Papers in Compendium

From: IJCS Editorial Office [ijcseditorial@yahoo.com]
Sent: Monday, October 26, 2015 6:33 PM
To: Flavin, Susan
Subject: Re: Permission to use published paper as part of dissertation compendium

CAUTION: External
Dear Ms Flavin,
You have my permission to use the full text of your article "Social Isolation and Its
Applicability to Persons with Sarcoidosis and Alpha-1 Antitrypsin Deficiency: A
Dimensional Concept Analysis", which appears in the latest issue of the International
Journal of Caring Sciences (Volume 8, Issue 3), as part of your dissertation
compendium.
I wish you good luck and every success in the defense of your dissertation.
Professor Despina Sapountzi-Krepia
Publisher and Editor in Chief, International Journal of Caring Sciences
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Permission to use published paper as component of dissertation compendium: IPHJ 7#3
Joav Merrick [Jmerrick@zahav.net.il]
Actions
To:Flavin, Susan
Inbox
Tuesday, October 27, 2015 12:00 AM
Retention Policy: Inbox (6 Months) Expires: 4/24/2016

CAUTION: External
You have permission to use your paper published in the Int Public Health Journal
2015;7(3) issue as part of your dissertation compendium, as long as you acknowledge the
original publication citation.
Good luck and all the best
Professor Joav Merrick, MD, MMedSci, DMSc
Editor-in-Chief----Int Public Health Journal
Specialist in Pediatrics, Child Health and Human Development
MINISTRY OF SOCIAL AFFAIRS AND SOCIAL SERVICES
Medical Director, Health Services
Division for Intellectual and Developmental Disabilities
Ministry of Social Affairs
POBox 1260
IL-91012 Jerusalem, ISRAEL
Tel: 972-2-5085522; Fax: 972-2-5085941; Mobile: 972-50-6223832
E-mail: yoavm@molsa.gov.il (for emails in Hebrew)
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Appendix F Demography Instrument (created by PI and refined by Dissertation Committee)

Demographic / Clinical Questionnaire
Age [Text Box]:

Please enter your actual age (in years)_____

Ethnicity*

Are you Hispanic, Latino/a, or Spanish origin
(one or more categories may be selected)
! No, not of Hispanic, Latino/a, or Spanish
origin
! Yes, Mexican, Mexican American, Chicano/a
! Yes, Puerto Rican
! Yes, Cuban

Race*

What is your race?
! White
! Black or African American
! American Indian or Alaska Native
! Asian Indian
! Chinese
! Filipino
! Japanese
! Korean
! Vietnamese
! Other Asian
! Native Hawaiian
! Guamanian or Chamorro
! Samoan
! Other Pacific Islander
! Other

Disability status*
During the past 30 days, for
about how many days did
pain make it hard for you to
do your usual activities,
such as self-care, work, or
recreation? [TEXT BOX]
During the past 30 days, for
about how many days did
fatigue or being extremely
tired make it hard for you to
do your usual activities,
such as self-care, work, or

___ days

___ days
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Age [Text Box]:
recreation? [TEXT BOX]
Are you deaf or have
serious difficulty hearing?
Are you blind or do you
have serious difficulty
seeing, even when wearing
glasses?
Because of a physical,
mental or emotional
condition, do you have
serious difficulty
concentrating,
remembering, or making
decisions?
Do you have serious
difficulty walking or
climbing stairs?
Do you have difficulty
dressing or bathing?
Because of a physical,
mental, or emotional
condition, do you have
difficulty doing errands
alone such as visiting a
doctor’s office or
shopping?
How many times have you
left your house/apartment
in the past week?

Please enter your actual age (in years)_____
! Yes
! No
! Yes

! No
! Yes

! No
! Yes

! No
! Yes
! No
! Yes

<Free text entry>

! No
Gender

! Male
! Female

Marital Status

! Married
! Single
! Divorced
133

Age [Text Box]:

Please enter your actual age (in years)_____
! Widowed
! Partnered (in a committed relationship)

Living Situation

! I live alone
! I live with a spouse / life partner
! I live with my child/children
! I live with spouse / life partner &
child/children
! I live with a friend
! Other

Annual income in the home

!
!
!
!
!

Number of years since
diagnosis

Enter actual number of years. If less than 1
year, enter “0”: ____

Condition

! Alpha-1
! Sarcoidosis

Genotype (if alpha-1)

!
!
!
!
!
!

Disease severity (if
sarcoidosis)

ZZ
SZ
SS
MZ
MS
Do not know

! Stage 1
!
!
!
!

Is another family member
involved who has the
disease

< $10,000/year
$10,000 - $24,999/year
$25,000 – $49,999/year
$50,000 – $99,999/year
≥ $100,000/year

Stage 2
Stage 3
Stage 4
Do not know

! Yes
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Age [Text Box]:

Please enter your actual age (in years)_____
! No

Do you participate in online
support groups?

! Yes

Do you participate in faceto-face support groups?
If “yes”, how many face-toface support groups per
year do you participate in?
Do you participate in any
advocacy groups

! No
! Yes
! No
____ [free text box]

! Yes
! No

Do you participate in any
activities/groups outside of
the home? (Check all that
apply)

!
!
!
!
!
!

Church
School / school groups
Sporting/physical activity
Book clubs
Social clubs
Other

*Categories adopted from Office of Minority Health. Final data collection standards for race,
ethnicity,
primary language, sex, and disability status required by section 4302 of the Affordable Care Act.
US Dept. of Health and Human Services. Accessed 20 Nov 2013: http:
//minorityhealth.hhs.gov/templates/browse.aspx?lvl=2&lvlid=208.
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Appendix G Friendship Scale
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Appendix H Instructions for Scoring Friendship Scale
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Appendix I Medical Outcomes Survey – Social Support Scale (MOS-SSS)
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Running Head: Social Isolation and Social Support in Alpha-1 and Sarcoidosis

Appendix J Instructions for Scoring the MOS-SSS
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Appendix K The modified Medical Research Council (mMRC) Dyspnea Score

Level of Dyspnea

Grade

1. I only get breathless with strenuous exercise.

0

2. I get short of breath when hurrying on level ground
or walking up a slight hill.

1

3. On level ground, I walk slower than people of the
same age because of breathlessness, or I have to
stop for breath when walking at my own pace on the
level

2

4. I stop for breath after walking about 100 yards or
after a few minutes on level ground

3

5. I am too breathless to leave the house or I am
breathless when dressing

4
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Appendix L Study Protocol

Medical University of South Carolina
Protocol
PI Name: Susan Flavin, MSN, RN
Study Title: A Mixed Methods Study of Social Isolation and Social Support in
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The purpose of this parallel convergent mixed-methods study is to describe perceptions of the
social impact of living with one of two rare diseases. The study will be guided by an interpretative
phenomenological approach, using semi-structured interviews and quantitative measurement of
perceived social isolation as measured by the Friendship Scale and perceived availability of
social support as measured by the Medical Outcomes . Qualitative data will be obtained via
interviews, transcribed, and analyzed via nVivo10. Quantitative data will be obtained via
participant completion of the Friendship Scale and the MOS-SSS, coded and uploaded into SPSS
v22 for analysis. Findings will be linked by a study ID number for comparison.
The rationale that underlies the proposed research is that prior to undertaking any large study to
assess the presence and magnitude of perceived effect of living with a rare disease on social
interactions, one must understand how it presents, what may ameliorate it, and what potential
interventions might be useful.
SPECIFIC AIMS
Aim #1: To explore perceptions of the social impact of living with rare disease by assessing
perceptions of social isolation, social support, connectedness, social participation and
relationships in adults with two rare lung diseases, AATD and sarcoidosis, in an academic center
and/or via the Web using one-on-one interviews.
Aim #2: To compare the Friendship Scale (Appendix 2) and the MOS-SSS (Appendix 3) in
individuals who have ever accessed compared to never accessed a support group in Alpha-1 and
Sarcoidosis. We will also evaluate these tools as measures of perceived social isolation and
availability of social support, respectively.
Aim #3: Triangulate the survey and interview results to identify areas for development of
interventions and preferences to improve individuals’ preferred level of social interaction.
Expected Results: The results will reveal some degree of social isolation in both groups, and the
isolation may be directly correlated with involvement in support groups (participation in online or
face-to-face groups = decreased perceived social isolation and perceptions of increased social
support).
Conclusion/Implications: The findings of the study will provide preliminary information useful
for refining hypotheses related to perceived social isolation and social support in rare disease
patients and to inform future intervention development.

B. BACKGROUND AND SIGNIFICANCE_________________________________
Many rare diseases are chronic, complex and associated with physical, intellectual or
neurological disabilities (Anderson, Elliott, & Zurynski, 2013). These conditions often accompany
significant psychosocial and emotional impact for patients and families, compounded by a lack of
support services. Functional limitations and the lack of support services can lead to perceptions
of social isolation. Over the past three decades, social isolation as a variable has been shown to
be predictive of mortality and morbidity in general population samples (House, 2001; House,
Umberson, & Landis, 1988, Brummet, et al, 2001) and in studies of diseased populations,
especially those suffering from cardiac disease (Berkman, 1995; Berkman & Syme, 1979 ).
Insight into factors contributing to perceptions of social isolation can be useful in designing health
promotion interventions (Berkman, 1995). Despite the number affected, rare disease patients
often feel isolated and unable to get the information and support needed (Colledge & Solly,
2012). Few published studies explore the psychosocial impact of living with a rare disease
(Wienke et al., 2014; Acorn, Joachim, & Wachs, 2003; Henderson, Packman, & Packman, 2009;
Stoller, Smith, Yang, & Spray, 1994). No published studies on social isolation in rare diseases
were identified, despite the fact that this phenomenon is repeatedly verbalized by individuals who
suffer from both diseases (personal communications, M. Judson, 2012, W. Hunter, 2013) and the
fact that individuals are encouraged to seek support (Lasker, Sogolow, & Sharim, 2005). Indeed,
the authors of a recent study of the association between the social environment and uncertainty
among a sample of patients with alpha-1 antitrypsin deficiency (AATD)-associated COPD have
called for more work evaluating the impact of social isolation and loneliness on individuals with
AATD(Hoth et al., 2014). The magnitude of perceived social impact of living with rare disease
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and its presentation in these individuals remains unknown. The risk of social isolation may be
high for persons with rare diseases such as sarcoidosis and alpha-1 antitrypsin deficiency
(AATD).
The long-term goal of this study is to refine hypotheses related to the perceived effect of living
with a rare disease on social interactions experienced by individuals with AATD and sarcoidosis
and to inform future intervention development. The overall objective of this study is to gain insight
into perceptions of the social impact, particularly social isolation and social support, and its
consequences as experienced by individuals with AATD and sarcoidosis. The overarching
question driving this proposal is: To what extent do individuals with the rare lung diseases of
AATD and sarcoidosis perceive the social impact and consequences of living with these diseases
as documented via participant self-report and as measured by the Friendship Scale and the
Medical Outcomes Study – Social Support Survey (MOS-SSS). The rationale for this study is
that results may yield information useful for refining hypotheses related to perceived social
isolation and social support in rare diseases and to inform future intervention development.
An estimated 10% of Americans live with a diagnosis of one of the 6,000 to 8,000 known rare
diseases (Griggs et al., 2009). The experience of living with a rare condition is complex and can
significantly affect the individual’s quality of life (Cohen & Biesecker, 2010). Many studies have
adopted a population-based approach to rare diseases, but the patients’ viewpoint on having
such a disorder has remained unattended (Huyard, 2009). These patients can experience a
myriad of psychosocial effects, including social stigma, lack of social support, and perceptions of
social isolation. In general, social isolation is gaining increased attention as an integral
component of health (World Health Organization, 2002) and the link between social isolation and
health is one focus of the National Research Council’s (National Research Council, 2001) interest
in integrative health. Social isolation as a variable repeatedly showed a predictive relationship to
mortality and serious morbidity both in general population samples (House, 2001; House,
Umberson, & Landis, 1988) and in studies of diseased populations, especially those suffering
from cardiac disease (Berkman, 1995; Berkman & Syme, 1979). In a recent review, (Cacioppo &
Cacioppo, 2014) found that social isolation can have a negative impact on executive functioning,
sleep, and mental and physical well-being, ultimately resulting in higher rates of morbidity and
mortality.
Social support as “the individual belief that one is cared for and loved, esteemed and valued, and
belongs to a network of communication and mutual obligations” (Cobb, 1976, p. 300). This too,
can be lacking in individuals who suffer from rare diseases. Strategies to ameliorate perceptions
of social isolation include various types of social support. The need for this is illustrated by the
European Union Committee of Experts on Rare Diseases (EUCERD) in their investigation into the
social support needs of individuals with rare diseases (2012). While the goal of this study is not
to investigate the effect of interventions, the perceptions of social support are important to
consider. As a first step, the perception of social support in these individuals is critical into
moving further in this work.
Few published studies have explored the experiences of living with a rare disease; no published
studies were identified that explored social isolation in rare lung diseases such as AATD or
sarcoidosis. Two studies conducted in the rare disease of scleroderma identified social isolation
as a phenomenon experienced by these individuals. Joachim & Acorn (2003) conducted a
phenomenologic study to investigate the perspective of living with scleroderma and identified
persistent themes of stigma and isolation. In their study of scleroderma patients, Cinar and
colleagues (2012) found similar themes, including social isolation. Henderson and colleagues
(2009) investigated the general psychosocial impact of living with Niemann Pick disease Type B,
a rare lysosomal storage disorder; they also observed that those patients reported feelings of
social isolation. McGarvey and Hart (2008) surveyed over 200 general practitioners in Ireland;
they found that 72% of GPs agreed that having a rare disorder gives rise to additional family
problems and 28% felt that rare disorders can result in feelings of isolation. No published studies
have focused solely on the phenomenon of perceived social isolation in individuals living with rare
diseases.
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Similar results were found when seeking to identify published studies on perceived social support
in either one of these conditions. No published studies were identified that explored perceived
social support in sarcoidosis. No such studies were identified which investigated perceived social
support in alpha-1 patients, although Hoth and colleagues (2014) found that in over 400
individuals with AATD, participation in support groups was associated with less ambiguity
surrounding the disease. In particular, a statistically significant impact on ambiguity was found in
those individuals who attended three or more support groups in the prior year compared with
individuals who reported no such participation (b =−3.31, SE=1.29, p=0.010)
Recognition of the importance of research into rare lung diseases has been growing (Gupta,
Bayoumi, & Faughnan, 2011). The contribution of the proposed research will explore and
compare the perceptions of social isolation and social support in two rare lung disease groups
from both the patient’s perspective, as well as quantitatively measure the magnitude of the
phenomenon.
Social isolation has been identified as a contributing factor for increased morbidity and mortality in
various populations (Cacioppo & Hawkley, 2003; Cacioppo, Hawkley, Norman, & Berntson, 2011;
Cornwell & Waite, 2009; Steptoe, Shankar, Demakakos, & Wardle, 2013). Despite confirmation
of perceived social isolation in Internet chat rooms, support group meetings, and limited studies of
rare disease patients (Black & Baker, 2011; Coulson, 2005; Coulson, Buchanan, & Aubeeluck,
2007; Lasker et al., 2005), there is a need for formal study that examines this phenomenon. The
contribution of this study will be significant because it will provide baseline data that can be
utilized to design larger studies in more diverse populations of rare disease patients, with the goal
of developing and testing interventions that can enhance social support and ameliorate the
condition of social isolation.
Despite the number of people affected by rare diseases, resources are lacking. Patients often feel
isolated, unable to get the information and support they need (Colledge & Solly, 2012). The
contribution of this research is aligned with the mission of the NINR, and specifically, the need to
“develop strategies to assist individuals and their caregivers in managing chronic illness, including
analyses of caregiver burden and cost-effectiveness” (National Institute of Nursing Research,
2011, p. 15). The contributions from this research will provide preliminary insights into the
management of the social isolation component of these rare, chronic diseases. Findings from
this study may be utilized to explore perceived social isolation and social support in other rare
disease populations.
Current clinical practice approaches the management of rare diseases primarily from the
biomedical approach, seeking to manage clinical physiologic symptoms (Budych, Helms, &
Schultz, 2012). Less attention is given to the psychosocial management of the impact of these
conditions. There remains little published evidence regarding the psychosocial burden of rare
diseases (Acorn et al., 2003; Barrow, 2011; Feinberg, Law, Singh, & Wright; Huyard, 2009;
Joachim & Acorn, 2003; McGarvey & Hart, 2008; Schieppati, Henter, Daina, & Aperia, 2008), and
no identified studies have explored perceived social isolation in these individuals. As these
patients may have significant needs and barriers to access to care (such as geographical
distance from an expert provider), alternative interventions to ameliorate the negative
psychosocial aspects of these conditions must be considered. In rare diseases, there is an
increasing importance and presence of the patient as an active participant in their disease
management and decisions (Aujoulat, Young, & Salmon, 2012; Aymé, Kole, & Groft; Black &
Baker, 2011; Johnson, Kirschenbaum, Mason, & Rush, 2005; Polich, 2012). As such, this
patient-centric focus calls for a parallel patient-centered research approach, such as interpretive
phenomenological analysis (IPA) (Smith, Michie, Stephenson, & Quarrell, 2002). Before
designing interventions, it is prudent to seek out the voice of the patient, and the qualitative
component of this study affords that opportunity.
The proposed research is innovative because this is one of the first (likely the only) identified
studies that explores perceived social isolation along with perceptions of availability of social
support in rare diseases. In addition, the study will employ a mixed-methods approach whereby
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the “voice of the patient” will be explored, via qualitative interviews, and findings from those
interviews compared with the perceived social isolation scores on a quantitative instrument
(validated in other adult populations, although not in rare diseases). The investigator’s
preliminary experience with previous qualitative interviews of AATD and sarcoidosis patients
suggests that individuals grappling with these rare conditions are eager and willing to give voice
to their concern.

C. PRELIMINARY STUDIES____________________________________________
The investigator is a doctoral student in the College of Nursing at the Medical University of South
Carolina, with a focus on the social burden of rare disease. Although not an academically funded
researcher, she has an established industry track record of over 17 years of pharmaceutical
clinical research experience, the last twelve in pulmonary research. For the past ten years, she
has successfully led clinical teams in the design, execution and management of various early
development studies, including two trials in the rare lung disease sarcoidosis, funded by her
employer, and where she was an internal employee of the company. Over the past four years,
she have successfully translated that experience and knowledge to doctoral studies, where
formal coursework is concluding. As a doctoral student at the Medical University of South
Carolina, she has been mentored in research involving rare disease populations under the
tutelage of an experienced nurse scientist whose focus is also rare genetic conditions and a
nurse scientist with expertise in community-based participatory research. The investigator also
successfully completed an independent research project requiring travel to the EU, recruit, enroll
and interview subjects for that project. As a result of her pharmaceutical and academic
experiences, she is cognizant of the need to plan appropriately, execute precisely, and
collaborate effectively and efficiently. In summary, the investigator possesses a demonstrated
record of accomplished and productive research projects in an area of high relevance for our
aging population, and her expertise and experience have prepared me to lead the proposed
project.

D. RESEARCH DESIGN AND METHODS (including data analysis) ____________
Overall Strategy. The mixed methods study design was informed by Creswell & Plano Clark
(2011). Semi-structured, individual interviews will be conducted to provide phenomenologic data
for thematic analysis (Braun & Clarke, 2006) to describe individuals’ perceptions of social
support, relationships with others, and preferences for support strategies. A quantitative
descriptive approach will involve participants’ completion of the Friendship Scale (Hawthorne,
2006), a six-item Guttman scale that measures social isolation and the Medical Outcomes Study:
Social Support Survey (MOS-SSS), a 19 item version instrument that measures perceived
availability of social support. A convergent design will allow the investigator to collect and
analyze two independent data streams in a single phase (Creswell & Plano Clark, 2011). After
merger, divergence, convergence and other relationships will be explored.
Sample Size Determination. Up to 275 participants will be enrolled in the trial, with the goal of
an equal distribution of AATD and sarcoidosis participants. In this mixed-methods pilot study, all
subjects will participate in the quantitative components and a subset (~30) will be requested to
participate in the qualitative interviews, although the interviews are not a requirement. If a robust
response is realized for the qualitative inquiry at the beginning of the study, the invitation for the
interview may be temporarily halted in order to allow the investigator to interview those interested
participants soon after their agreement to be interviewed. This size is robust for a pilot qualitative
approach; other qualitative studies of rare disease participants have enrolled less than 20 per
group (Bogart, Tickle-Degnen, & Joffe, 2012; Joachim & Acorn, 2003). Guidelines for sample
size for studies using an interpretative phenomenological approach suggest that between 3-6
participants per group is reasonable; this provides sufficient cases for analysis without the risk of
any overwhelming volume of data (Smith, Flowers, & Larkin, 2011). Other descriptive studies of
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rare disease groups have typically included less than 50 participants (Anderson et al., 2013).
Some researchers have also suggested that saturation in qualitative interviews may occur early.
Guest, Bunce, & Johnson (2006) evaluated data from a study involving sixty in-depth interviews
with women in two West African countries and documented the degree of data saturation and
variability over the course of thematic analysis. They found saturation occurred within the first
twelve interviews, and further, basic elements for themes appeared as early as after the first six
interviews. Based upon the previous points, the proposed sample size is a reasonable goal.
The study will be introduced to potential subjects as a study that consists of two parts, an
“interview” portion and a “questionnaire” portion. For the purposes of this study, caregivers will
not be included as part of the study population. If subjects agree to participate in both parts, the
preference is for the qualitative interview will be conducted first, followed by the quantitative
component, but will be subject to participant availability and logistics. In this study, caregiver is
defined as the individual who acts as a support person for the individual with the rare condition;
typical examples include a spouse/partner, other relative or friend who provides physical and/or
emotional support (Burns, et al, 2005).
•

Eligibility Criteria
o Inclusion
! Participants will be eligible to participate in the study if they meet the
following criteria:
• Adult participants (male or female) ≥18 years of age
• Self-report a physician diagnosis of AATD or sarcoidosis with
pulmonary involvement
• Self-reported ability to read and speak English
• Have access to a computer with a valid email address (for
purposes of completing instruments via REDCap)
o Exclusion
! Participants who self-report that they are caregivers, or have diagnoses
other than AATD or sarcoidosis

For the purposes of presenting the research design and methods, each one of the three
individual aims will be presented individually:
Aim #1: To explore perceptions of the social impact of living with rare disease by
assessing perceptions of social isolation, social support, connectedness, social
participation and relationships in adults with two rare lung diseases, AATD and
sarcoidosis, in an academic center and/or via the Web using one-on-one interviews.
Introduction In rare diseases, it is critical to obtain the voice of the patient (Patsos, 2001). The
objective of this aim is to elucidate individuals’ perceptions of social isolation, social support,
relationships with others, and preferences for support strategies. This approach has been used
successfully in other studies investigating living with a rare disease (Feinberg et al., 2013;
Joachim & Acorn, 2003; Vitale, 2005). To attain the objective of this aim, individual interviews will
be conducted. The rationale for this aim is gather information related to individuals’ experiences
related to social support and social isolation, without imposing bias from predefined questions
and/or categories.
Data Collection. For Aim #1, a semi-structured interview guide will be utilized for the purposes
of conducting participant interviews. Interviews may take place in a face-to face setting, via
phone, or via Skype® (or a similar web-based videoconferencing program). Following agreement
to participate (via receipt of the Information for Survey Participants document) and during the
interviews, the dialogue will be audio-recorded for the purposes of later transcription. For those
subjects who may be participating via telephone or Skype® interviews, a script will be followed to
ensure compliance to all verbal interview guidelines. This type of interview approach is based on
a flexible topic guide that provides a loose structure of open ended questions to explore
experiences and attitudes (Pope, van Royen, & Baker, 2002). In a hermeneutic approach to
interviewing, the interviewer is the instrument and requires attention to the co-creation of the data
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through the interaction between participant-respondent and interviewer (Lowes & Prowse, 2001).
The interview script, comprised of eight questions, is designed to facilitate approximately 60-90
minutes of dialogue. The interviews will take place either face-to-face or via phone or Skype® for
participants that are enrolled via the Internet.
This Heideggerian hermeneutic approach (Lowes & Prowse, 2001) will shape the interview and
describe from a participant perspective, individuals’ experiences in terms of living with a rare
disease. Semi-structured questions and prompts are used to yield narratives centering on social
isolation and/or social support (“tell me a little bit about the people you interact with during a
typical day”; “tell me about who you could call on in times of need.). This approach will allow the
researcher to utilize previous knowledge gained to guide the inquiry (Lopez & Willis, 2004).
Data Analysis: Interviews will be transcribed verbatim. The investigator will also maintain field
notes to be used as a reference point and reflexive tool during data analysis. After conduct of
and transcription of the interviews, all data will be uploaded into nVivo10. Following the
guidelines prescribed by Smith et al., (2011), the investigator will seek immersion in the data by
reading and re-reading each individual transcript. Initial coding will occur on an exploratory level,
followed by a more refined review looking for emerging themes (Smith et al., 2011). Interview
transcripts will be coded line-by-line and codes will be developed themes and subthemes, as
suggested by (Braun & Clarke, 2006). After initial themes are identified, additional data
abstraction will occur. Following this inductive approach, data will be revisited to see if any
reorganization of categories or themes should occur (Creswell & Plano Clark, 2011). As an
example of this approach, transcribed text that references support groups, online groups or
advocacy involvement might code initially to a super-ordinate theme of “social support options”.
Themes will be summarized using frequencies and percentages. Data may be compared
(between the two disease groups) using Fisher’s exact test, in order to identify substantial
differences in the responses between the two populations.
In addition, the number of attempted interviews compared with the number of completed
interviews will be summarized.
Expected Outcomes. It is expected that participant interviews will yield information related to
varying degrees of social support, perceived social isolation, and measures individuals have
taken in the past to address their feelings. It is also expected that some subjects may not have
taken any steps to address their feelings of being socially isolated. Analysis of themes is
expected to generate inferences regarding the predominant themes in each sub-population, as
well as the overall study population.
Potential Problems and Alternative Strategies. There are a number of potential problems that
could arise as a result of the subjective nature of the qualitative approach. Difficulty establishing
rapport with potential subjects could arise. For this particular study, the researcher will begin the
interview with small talk and remind participants of their valuable contribution to the study. Social
desirability is another form of bias that may be present. The population under study are both
AATD and sarcoidosis participants who may suffer from the stigma of their disease, and may
eagerly welcome the researcher’s attention. As DiLorio suggests (2005) some individuals may
respond in an optimizing or satisfying approach, or conversely, acquiesce and act as a naysayer
(p 44). Qualitative research is prone to bias due to the inherent preconceptions and attitudes of
the researcher (Hewitt-Taylor, 2001). Self-examination on the part of the researcher of their
beliefs and attitudes can help to mitigate this risk.
Aim #2: To compare the Friendship Scale and the MOS-SSS in individuals who have ever
accessed compared to never accessed a support group in Alpha-1 and Sarcoidosis. We
will also evaluate these tools as measures of perceived social isolation and availability of
social support, respectively.
Introduction. Pilot studies can be invaluable when assessing the feasibility of a planned design,
the practicality of a given instrument, recruitment rates, and any data management issues that
might occur, including response rates to questionnaires (Arain, Campbell, Cooper, & Lancaster,
2010; Thabane et al., 2010). This approach can be particularly useful when evaluating an
existing instrument in a new population. Hawthorne (2006) suggests that when measuring social
isolation in any population, brief scales that offer ease of administration and interpretation are
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advantageous, such as the Friendship Scale. Response rates have been shown to be inversely
correlated to questionnaire length (Edwards, Roberts, Sandercock, & Frost, 2004), although this
relationship continues to be explored, and remains a topic of debate (Rolstad, Adler, & Rydén,
2011). The objective of this aim is to gain a sense of the magnitude of perceived social isolation
and social support in the overall population, as well as within sarcoidosis and alpha-1 subjects.
To attain the objective of this aim, subjects will be asked to complete the instruments via an
electronic link to the REDCap site, where the instruments for the study will be located. Although
the preference is for qualitative interviews to be completed prior to completion of the instruments,
the timeframe of when subjects are available for interviews versus completion of the instruments
may not support this preference. As such, subjects will be encouraged to complete the
instruments at their convenience, irrespective of their willingness to participate in qualitative
interviews. The rationale for this aim is that comparison and contrast of scores will provide
valuable insights into the magnitude of perceived social isolation, and also assess the feasibility
of the instruments in these populations.
Data Collection. For Aim #2, four instruments will be utilized for the quantitative component of
the study: a general demographics questionnaire, the modified Medical Research Council
(mMRC) Dyspnea Score (to characterize perceived breathlessness), an instrument to measure
perceived social isolation (The Friendship Scale) and an instrument to measure perceived
availability of functional support, the Medical Outcomes Study – Social Support Survey (MOSSSS).
The demographic instrument, designed by the investigator, will collect information related to age,
ethnicity, race, disability status, pain, fatigue, frequency of leaving the home, gender, marital
status, living situation, income, years since diagnosis, condition, genotype (if AATD), disease
severity (sarcoidosis), familial history of the respective condition, participation in support or
advocacy groups (and the number of meetings attended) and participation in outside activities, by
study population as a whole, as well as by disease condition (Appendix 6).
The second instrument is the modified Medical Research Council (mMRC) Dyspnea Score, a five
item, standardized, self-administered scale to quantify the effects of breathlessness on everyday
activities. The scale is used to document the impact of dyspnea on the subject’s physical
functioning. A 5 point scale uses statements about perceived breathlessness graded from 0 to 4
demonstrating increasingly severe loss of function (Bestall et al, 1999; Papiris et al, 2005).
Dyspnea is rated in the present timeframe. The scale has been used successfully with subjects
aged 6 to > 80 years (Darbee and Ohtake, 2006) with a completion time of approximately 5
minutes.
The third instrument is the Friendship Scale, a six-item Guttman scale that measures social
isolation (Hawthorne, 2006). The psychometric properties of the scale in the validation study
conducted in older adult populations living in various types of settings (nursing homes, hospital
outpatients, older veterans, and community members) suggest that it has excellent internal
structures as assessed by structural equation modeling (CFI = 0.99, RMSEA = 0.02), that it
possesses reliability (Cronbach’s alpha = 0.83), and discrimination when assessed against two
other short social relationship scales (Hawthorne, 2006; Hawthorne, de Morton, & Kent, 2013;
Nikmat, Hawthorne, & Al-Mashoor, 2013). A subsequent validation study in individuals with low
back pain showed similar results (Hawthorne et al., 2013). The scale has been used in a study of
over 3,000 community-dwelling residents of Australia, ranging in age from adolescence to the
elderly. Use of the Friendship Scale in any rare disease population has not been identified in the
published literature. However, the consistent psychometric results of the scale in diverse
populations suggest that the scale may possess similar validity in the populations under
consideration, although this needs to be explored.
Tests of concurrent discriminant validity suggest it is sensitive to the known correlates of social
isolation (Hawthorne, 2006). The scale covers both critical aspects of social isolation: perceived
social isolation and perceived emotional loneliness. Three of the six items assess perceived
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social isolation and the other three assess perceived loneliness. Scores for each item range from
zero to 4; an individual’s total score on the instrument can range from zero to 24. Scoring is by
simple summation. Cutpoints to classify different levels of social isolation are as follows:
•
0-11: Very socially isolated
•
12-15: Isolated or with a low level of social support
•
16-18: Some social isolation or some social support
•
19-21: Socially connected
•
22-24: Very or highly socially connected (Hawthorne, 2006).
Finally, the fourth instrument is the Medical Outcomes Study: Social Support Survey (MOS-SSS).
This is a 19 item version instrument that measures perceived availability of social support. It
contains four domains to assess perceived availability of social support, including (1) emotional/
informational support, (2) tangible support, (3) positive social interaction and (4) affectionate
support (Sherbourne & Stewart, 1991). Responses are given by the subject using a 5 point
Likert-type scale, and range from “none of the time” to “all of the time”. Scores range from 0-100
with higher scores indicating more perceived support. The MOS-SSS has been utilized
extensively in various populations (Carod-Artal, Ferreira Coral, Trizotto, & Menezes Moreira,
2009; Cuijpers, 2001; Duncan et al., 1997; Sherbourne & Stewart, 1991), and more recently, in
studies of social support in COPD patients (Zijing et al., 2014)
All instruments will be completed by the subjects, at a time convenient to them and accessed via
an electronic link sent to them via email.
Power Analysis
The sample size calculation is based upon the Friendship Scale. In the general population, the
mean total score for the Friendship Scale was 21 (SD 3.47) (Hawthorne, 2006)( We hypothesize
that the total Friendship scale score reflecting social connectedness for the entire study
population is 20 representing a difference in total scores of 1 point on the Friendship scale. To
have 80% power to detect a difference of 1 point in total scores between the general population
and the study sample of alpha-1 and sarcoidosis patients, assuming a common standard
deviation of 4.0 for alpha=0.025 (one-tailed test), 126 subjects are required. The assumption of
a lower score for the disease groups under study is based upon references in the literature which
suggest some degree of social isolation in these individuals (Colledge & Solly, 2012), although
that has not been formally tested. For further comparison of social connectedness between the
two disease subgroups (alpha-1 versus sarcoidosis) with 60 participants per group we will have
80% power to detect a two point difference in total Friendship scores between the groups
assuming a common standard deviation of 4.0 for a two-tailed t-test (alpha=0.05).
Data Analysis:
Subjects will complete the questionnaires in REDCap. Data from REDCap will be exported to
SPSSv22 for analyses.
o Descriptive statistics will be computed on the demographic and clinical characteristics
of the study population.
o Where appropriate, and for categorical variables including ethnicity, race, gender,
marital status, living situation, income, disease condition, genotype (if AATD) or
staging (if sarcoidosis) activities, participation in support groups, hearing and
sight status, and challenges with stair climbing and/or dressing or errands,
frequencies (both absolute and relative) will be reported for each item.
o For ordinal variables, such as years since diagnosis and income, frequencies
(absolute and relative) will be reported.
o For the continuous variables of age, number of years since diagnosis, pain and
fatigue day counts, and days that the subject has left their house, measures of
central tendency including mean, median and standard deviation will be reported.
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o

o

o

o

o

Disease groups will be compared with respect to their demographic and clinical
characteristics using t-test and chi-square tests as appropriate for continuous and
categorical variables, respectively. If non-normality is observed appropriate nonparametric tests will be used instead.
Feasibility of the instruments will be examined by assessing recruitment rates,
completion rates and time to completion. Participants will be asked to rate both
instruments in regard to ease of completion (very easy to complete/easy to
complete/hard to complete/very hard to complete) (see Appendix 5).
o Recruitment patterns will be examined
! Numbers of potentially eligible subjects versus number who consent to
participation will be reported as proportions
• Number of completed instruments versus number of attempted
instruments will be reported using proportions.
• A “completed” instrument is defined as an instrument where
>90% of the items have been responded to by the subject.
o For the Friendship Scale, the subject will enter a
response to the 6 questions
o For the MOS-SSS, the subject will enter a response to
the 19 items
• For those instruments with missing scores, missing values will be
assumed to be missing at random, and imputed using the
Individual mean imputation approach.
o The imputed value is the calculated mean of a given
subject's complete responses to other questions. If a
participant has 2 missing responses, the values are filled
with the calculated average of the remaining completed
18 questions (Shrive, Stuart, Quan, Ghali, 2006).
o Faciliators and barriers to recruitment will be examined in anticipation of their
impact on subsequent trials
! Use of patient advocacy contacts, clinician-experts, social media
outreach will be considered and reported as well as the number of
enrolled participants that come from these various methods
! For those subjects who participate in the qualitative portion of the study,
prompts will explore the reasons for participation.
Differences between completion rates will also be examined.
o Completion rates will be summarized and compared using an ANCOVA model by
ease of completion (easy/not easy), mode of delivery (‘live” versus electronic)
and disease population (sarcoidosis / alpha-1)
! The Kruskal-Wallis test will be used to compare completion rates by
income level. Chi-square, df and significance will be reported
o Ease of completion will be summarized and compared using the Cochran–
Mantel–Haenszel test, stratifying on income and disease.
Reliability
o Reliability will be explored by calculating Cronbach’s alpha for the overall
population and each disease population. For the Friendship Scale, a will be
reported for the overall scale. For the MOS-SSS, a will be reported for both the
subscales as well as the overall instrument.
Validity
o Content validity will be assessed by presenting the two scales to three experts
in the field prior to having any subjects complete the questionnaires: (1) a
sarcoidosis expert, (2) an alpha-1 antitryspin deficiency expert and (3) an expert
in the area of instrument development. Although not expert in the field of patientreported outcomes, the scales will be presented to two expert, disease-specific
clinicians to assess clinical relevance.
o Concurrent validity will not be explored at this time due to the limitations of the
study size and time.
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Convergent validity will be explored by correlating scores on the Friendship
Scale with scores on the MOS-SSS; it is hypothesized that higher Friendship
Scale scores will correlate to lower MOS-SSS scores (indicating less perceived
support).
Social isolation and social support scores:
For the Friendship Scale, negatively worded items (items 1, 3 and 4) will be reverse
scored so that their valence matches the positively worded items (Hawthorne, 2006).
For the MOS-SSS, scores for each subscale will be obtained by
o First, individually calculating the average of the scores across all respective items
in each subscale.
o An overall support index will be calculated by summing the average of
! the scores for all 18 items included in the four subscales, and
! the score for the last item of the scale, which asks the subject if they
have “someone to help them keep their mind off of things”. This last item
is not included in the 4 subscales
o Finally, scores will be transformed to a range of 0 to 100 using the developers’
instructions and the following formula (Sherbourne and Stewart, 1991):
o

o
o
o

100𝑥(𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑  𝑠𝑐𝑜𝑟𝑒 − 𝑚𝑖𝑛𝑖𝑚𝑎𝑙  𝑝𝑜𝑠𝑠𝑖𝑏𝑙𝑒  𝑠𝑐𝑜𝑟𝑒)
(𝑚𝑎𝑥𝑖𝑚𝑢𝑚  𝑝𝑜𝑠𝑠𝑖𝑏𝑙𝑒  𝑠𝑐𝑜𝑟𝑒 − 𝑚𝑖𝑛𝑖𝑚𝑎𝑙  𝑝𝑜𝑠𝑠𝑖𝑏𝑙𝑒  𝑠𝑐𝑜𝑟𝑒)
!

!

Mean total scores (with 95% CIs) will be calculated for the pooled study population
(alpha-1 and sarcoidosis subjects) for both the Friendship Scale and MOS-SSS.
o Subsequently mean total scores (with 95% CIs) will be calculated for the
individual disease groups for both scales. The mean scores of each disease ;)
o group will be compared with the mean score for the overall study population.
o The pooled study population will be dichotomized into individuals who have
accessed online or face-to-face support groups and those who have not
accessed such groups.
! We will compare mean total scores (with their 95% CIs) for both the
Friendship Scale and MOS-SSS to determine if there is a difference
between the groups of subjects who have accessed compared to not
accessed online or face-to face support groups. ,
! In addition we will compare the means for these tow groups stratified for
disease state. Independent t-tests will be used to examine the
differences in the Friendship Scale and MOS-SSS scores between
individuals who have accessed online or face-to-face support groups and
those who have not.
! Results will include the t-statistic, the df, and the degree of significance.
! If non-normality is observed, alternatively, Wilcoxon rank-sum tests will
be utilized to examine the difference in the Friendship Scale and MOSSSS scores between individuals who report access to online or face-toface support groups.
• Results will include W, the z-score and the significance level,
along with the median score. Mean scores (and SDs) will also
be reported, if careful consideration of outliers merits inclusion of
the value.
Exploratory logistic regression will be used to determine whether any of the demographic
or clinical characteristics might be predictive of higher/lower social isolation or social
support scores.
o The Friendship Scale will be dichotomized into those who were very isolated,
isolated, and with some isolation [range of scores 0-18] versus the socially
connected and very socially connected [range of scores 19-24]) (Hawthorne, de
Morton, & Kent, P. (2013).
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The MOS-SSS will be dichotomized to indicate those who perceive low-normal
social support (below 75th percentile) or high social support (above or equal to
the 75th percentile) (Sherbourne, Meredith, Rogers and Ware,(1992).
Odds ratios (with 95% CIs) for each predictor will be calculated and presented. Of
particular interest are age, sex, race, education level, pain scores, and disease severity
indices.
o Missing values will be assumed to be missing at random, and will be imputed
using the multiple imputation procedure available in SPSS.
o

!

95% confidence intervals will be calculated and presented to provide measures of precision of the
outcome estimates.
Expected Outcomes. It is expected that the analyses of the quantitative scores will generate
inferences regarding the magnitude of perceived social isolation in each sub-population, as well
as the overall population. There may also be some outlier scores; these scores will be examined
individually, as well as in the context of the individuals who completed those respective
instruments.
Potential Problems and Alternative Strategies. The expectation is that participants in the
overall population will report some degree of social isolation, as measured by the Friendship
Scale. The literature review, albeit brief, supports this expectation. However, there is the remote
possibility that this is not the case, and that some subjects do not report perceptions of social
isolation. In that event, the demographic questionnaire and qualitative interviews would be
reviewed for confirmation of participation in support groups, advocacy efforts and/or strong
family/friend support. These potentially confounding variables could also explain why some
individuals do not report perception of isolation.
Various measurement errors can occur with the use of the Friendship Scale. Random error can
occur because of noise or distraction and as a result, the participant enters incorrect responses.
Idiosyncratic error also is possible, since three of the item responses are reversed. It is possible
that participants could indicate the wrong response due to the preceding response. The potential
for social desirability response bias exists, in that participants might provide responses for which
they think that the researcher will approve. To mitigate this risk, the researcher will sit quietly with
each participant, allow a dialogue to occur, and remind them that the researcher is not there to
judge, but to collect the most precise data possible. “Faking bad” occurs when a participant
answers in a more negative manner because they think that they might benefit from it (Di Lorio,
2005). The researcher has included information in the Information for Survey Participants form
that details the expectations of the participant and the consequences of participating in this
research study. The Friendship Scale has a 4-week recall period. This can be challenging,
especially if the participant responds quickly to the question, rather than considering the recall
period (Di Lorio, 2005). One way to mitigate this would be to conduct cognitive interviews to
understand what participants are thinking as they respond to the questions (Nápoles-Springer,
Santoyo-Olsson, O'Brien, & Stewart, 2006). However, this would not be optimal in this case due
to the time constraints of the current study. The researcher will remind each participant of the 4week recall period prior to the participant completing the scale. The scale is self-administered by
the participant. As DiLorio (2005) suggests, an introductory cover letter may help to ameliorate
incorrect responses, by helping to focus the participant and put them in the proper frame of mind.
Environmental factors that could cause measurement error could be an overcrowded room,
where the participant might not be comfortable (for the face-to-face cohort) or lack of familiarity
with the computer (for the web-based cohort).
Aim #3: Triangulate the survey and interview results to identify areas for development of
interventions and preferences to improve individuals’ preferred level of social interaction.
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Introduction. Triangulation of data can enhance completeness and trustworthiness of the work,
in addition to providing for a more in-depth analysis of the findings. The approach of combining
closed-ended questionnaires, like the Friendship Scale, with qualitative interviews, such as the
one proposed, is one of the most common mixed-methods approaches in the literature (Creswell
& Plano Clark, 2011). As this parallel, convergent, mixed-methods design is intended to be
exploratory in nature, the objective of the triangulation of data from both the quantitative and
qualitative strands is to combine or link the findings into meta-inferences of the study findings as
a whole (Teddlie & Tashakkori, 2009). To attain the objective of this aim, after concurrent data
collection, both data streams will be independently analyzed. Based upon the findings, specific
dimensions will then be identified on which to compare the findings (Creswell & Plano Clark,
2011). The rationale for this aim is that subjective narratives may identify areas for further item
development not captured in the Friendship Scale and provide insights into intervention
development. When the triangulation of data is completed, it is the investigator’s expectation that
the results will yield information to provide for further refinement of subsequent larger studies,
with an eye towards identification of possible strategies that can ameliorate perceived social
isolation.
Triangulation:
This project combines qualitative and quantitative data from multiple data sources to support a
preliminary, yet comprehensive evaluation of the perceived social impact of living with a rare
disease. Triangulation of data and methods provides a more holistic and contextual
representation of the phenomenon under investigation, and reveals the varied dimensions of the
phenomenon, with each source contributing an additional piece to the puzzle. In using
triangulation, bias can be minimized and validity enhanced.
In this study, the investigator will implement the process of conceptual triangulation described by
(Foster, 1997). Conceptual triangulation involves "a search for logical patterns of relationship and
meanings between the variables measured by either or both qualitative and quantitative
methods." (Mitchell, 1986, p25) This process is designed to achieve a more complete and
contextual portrayal of the phenomenon of interest. The process of conceptual triangulation
involves five steps: 1. conducting qualitative and quantitative research true to the paradigmatic
assumptions of each methods,2. distinguishing pertinent results within each methods, 3.
examining confidence in the results, 4. developing criteria for inclusion of results in the conceptual
model, and 5. constructing one or more preliminary conceptual models of the social impact of a
rare disease. Due to the limitations of this dissertation study (sample size, study populations,
time and budget constraints), the development of such a model may not be possible, but will be
considered throughout all phases of the research process.
Research Design. Following completion of Aims #1 and #2, data will be compiled for
triangulation. The matrix below presents the planned triangulation strategy:
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Method Data Collection
Qualitative
Subject Interviews

Type of Triangulation
Within Method
Investigator

Field notes

Investigator

Quantitative
Friendship Scale
MOS-SSS
mMRC-Dyspnea

Between Method
Data

Method of Analysis

Purpose/Goal

Audio-recorded, ,
transcribed, analyzed for
themes
Analysis of text

Deepening understanding
of subjective experiences

SPSSv22; descriptive
analyses;
inferential analysis
using non-parametric
statistical tests; chisquare analysis,
exploratory logistic
regression

Triangulation of
qualitative data with
results of the scale to
determine if interview
findings are reflected in
scale scores

Document observations,
scenarios, not easily
interpreted from text

	
  
As data will have been reviewed separately for Aim #1 and Aim #2, this third Aim will employ
revisiting the data as a whole, to assess for convergence of divergence of findings.
Expected Outcomes. This is the first known mixed methods study to explore any psychosocial
phenomenon in rare disease patients. It is anticipated that the results may reveal some degree of
social isolation in both groups, and the isolation may be directly correlated with disease severity
(more severe disease equates to increased perceived social isolation). Phenomenological
findings may add rich information regarding the characteristics of perceived social isolation that
cannot be measured with the Friendship Scale. In addition, it is anticipated that qualitative
responses detailing participants’ previous experiences with support groups or activities will inform
future studies designed to investigate various interventions. Themes that reflect coping with or
decreasing social isolation will be used in hypothesis generation and a later process of
intervention mapping (Kok, Schaalma, Ruiter, van Empelen, & Brug, 2004). Inferences from the
QUAN and QUAL datastreams will inform meta-inferences for the overall study.

E. PROTECTION OF HUMAN SUBJECTS_________________________________
1. RISKS TO THE SUBJECTS
Human participants affected by rare lung diseases can experience a number of various
psychosocial challenges related to their rare disease, including perceptions of social isolation.
The cause of these perceptions is the topic of this proposed research. Approximately 275 human
participants (with the goal of enrolling an equal number of sarcoidosis and alpha-1 subjects) will
be invited to take part in this study to assess and compare perceptions of social isolation. Human
participants will take part in individual interviews as well as completion of a short, quantitative
questionnaire. The investigator will be the sole individual conducting the interviews and
administering the questionnaire at a single time point. Interviews are planned to be conducted
face-to-face; however, telephone or Skype interviews may be utilized.
Subject Population Characteristics. The collaborating academic institution, the Medical
University of South Carolina, is a large academic institution with established clinics that serve a
large population of alpha-1 and sarcoidosis patients, respectively. The investigator has
established previous academic relationships with the collaborating physician, Dr. Charlie Strange
(MUSC). The Alpha-1 Research Registry, located at MUSC, has currently enrolled over 3300
individuals with Alpha-1 Antitrypsin Deficiency (Alpha-1 or AAT Deficiency) or a carrier phenotype
willing to participate in Alpha-1 research. The Registry was established in 1996 by the Alpha-1
Foundation in accordance with recommendations of the World Health Organization, to facilitate
research initiatives and promote the development of improved treatments for Alpha-1 Web-based
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support groups that the investigator belongs to, (including the Alpha-1 support group and the
Sarcoidosis Online Sites groups) have more than 600 and 1800 members, respectively. In
addition, subjects may be recruited via postings on the NORD (National Organization for Rare
Disorders) and INSPIRE (an online community for individuals with rare conditions) websites. It is
anticipated that the average age will be 50 years, ~60% female, ~40% male, approximately 40%
black (primarily driven by the sarcoidosis population), 60% white.
We anticipate <1% of the population will be Hispanic, which reflects the ethnic make-up of the
recruitment area. We will include English-speaking participants only due to the pilot nature of the
study, limited resources and the special needs of bilingual and culturally sensitive
protocol/materials. Children will not be included as sarcoidosis is generally limited to adults, and
alpha-1 antitrypsin deficiency with lung involvement is also very rarely identified in children.

Targeted/Planned Enrollment Table
Total Planned Enrollment 275
TARGETED/PLANNED ENROLLMENT: Number of Subjects
Sex/Gender
Ethnic Category
Females
Males
Hispanic or Latino
2
3
Not Hispanic or Latino
200
70

Total
5
270

Ethnic Category: Total of All Subjects*
Racial Categories
American Indian/Alaska Native
Asian
Native Hawaiian or Other Pacific Islander
Black or African American
White
Racial Categories: Total of All Subjects*

0
0
0
50
110
160

0
0
0
50
65
115

0
0
0
100
175
275

b. Sources of Materials
Materials obtained from the participants include questionnaires and interviews. Demographic data
includes information related to age, ethnicity, race, disability status, pain, fatigue, gender, marital
status, living situation, income, years since diagnosis, condition, genotype (if AATD), disease
severity (sarcoidosis), familial history of the respective condition, participation in support or
advocacy groups (and the number of meetings attended) and participation in outside activities, by
study population as a whole, as well as by disease condition (Appendix 7). These data will be
collected from interviews by the investigator to further characterize and describe the sample. The
questionnaires (demography, the Friendship Scale, the MOS-SSS, and the mMRC Dyspnea
Scale) can be done in less than 30 minutes to reduce participant fatigue and burden. Participants
will enter their own data into REDCap via an electronic link sent to each participant via email.
Access to the REDCap database will be given to the investigator’s advisor.
c. Potential Risks
There are potential risks inherent to any type of interview approach such as psychosocial impact
and increased focus on the negative aspects of any condition. There is minimal risk to the
participants in terms of acute injury as no interventions will be performed. Consenting
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participants will respond to interview, demographic and scale questions as described above.
Breach of confidentiality is a potential risk. It is possible that individuals familiar with study
subjects at a particular research site could identify those subjects who participate in this study.
Personal identifying information will not be stored with data.

F. ADEQUACY OF PROTECTION AGAINST RISKS
a. Recruitment and Informed Consent
Recruitment. Access to participants will be facilitated through an established relationship with a
clinician expert located at the Medical University of South Carolina. In addition, the investigator
has established a network of patient contacts who participate in Web-based support groups (such
as www.Inspire.com and NORD (National Organization for Rare Disorders
(www.rarediseases.org) and other rare disease initiatives. Representatives from these
organizations have been contacted and are amenable to posting notification of the study on their
Web pages and/or Facebook pages. Prior to study commencement, these individuals have been
contacted and informed about the study with the intent of collaborating with them as a source of
potential participants. Web-based recruitment may be utilized to enroll a portion of the
participants in the study. In rare disease research, the internet has been a key and expanding
method for recruiting clinical study participants and publicizing new studies and/or areas of focus
(Griggs et al., 2009; Schumacher et al., 2014).
Informed Consent
The study seeks a waiver of informed consent, since no interventions are being performed.
Subjects may be accessed via the following avenues:
• Dr. Charlie Strange at MUSC
• The Inspire website,
• The NORD Facebook page
• Via previous patient contacts known to the investigator, including patient support
groups.
Study Procedures
All potentially interested subjects will be provided with the email and phone number of the
investigator.
• They will be asked to contact the investigator for further information, and to provide their
first name, last initial, contact email and phone number.
• For these subjects, a prenotice letter will be sent (via email) that acquaints them with the
study and explains the purpose of the current data collection.
o A second follow-up email contact and a follow-up phone call (where possible) will
be used to bolster participation of those who do not respond to the initial mailing.
• The prenotice letter will be followed with by an email containing an electronic link
directing them to the REDCap link which will include an Information for Survey
Participants document, a patient information module (requesting first name, last initial,
phone number, email and the electronic versions of the instruments.
Quantitative Procedures (REDCap Survey)
• Once entering the REDCap site, the first module that the subjects will see is the
Participant Information Survey (5 items), which collects the first name, last initial, email
address and phone number.
o In addition, the last question in the Participant Information Survey section of the
REDCap site asks the subjects specifically if they would be willing to participate
in the qualitative interview.
o “Would you be willing to participate in a short (30 minute) interview with the
investigator, in addition to responding to the surveys here?”
o If the participant responds yes:
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They can continue through the REDCap site, complete the
survey/instruments, and be contacted by the investigator to determine a
mutually agreeable time to be interviewed
! Alternatively, the can opt to complete the interview prior to completing
the surveys.
• Both options are at the discretion of the subject, and intended to
decrease respondent burden
• The investigator receives notification when a new subject has
accessed the REDCap site, and so will be made aware of any
new/potential participants
! If the interview is conducted in person, it may be conducted either at the
MUSC clinic site of Dr. Strange, or at a mutually agreeable location (for
both subject and investigator) if the participant is local to the investigator.
! The interview will be audio-recorded and transcribed at a later date for
purposes of qualitative coding and analysis.
! No protected health information (PHI) will be collected, other than the
participant’s first name, last initial, and diagnosis.
If the participant responds “no”
! They can continue through and complete the online surveys.
!

o

•

•

•
•

•

The next module that the subjects will complete is the Demography module (26 items),
which asks questions about the subject’s age, race, levels of pain, fatigue, impairments of
hearing, vision, concentration, mobility, ability to perform activities of daily living, gender,
marital and living situation status, levels of income and education, disease and duration
of condition, participation in support groups and other activities.
The third module that the subjects will complete is the modified Medical Research
Council (mMRC) Dyspnea Scale, a 5 item scale that asks the subject about their level of
perceived dyspnea
The fourth module is the Friendship Scale, a 6 item scale that inquires about the subject’s
perceptions of social isolation
The fifth module, the Medical Outcomes Study: Social Support Survey (MOS-SSS), is a
19 item instrument that measures perceived availability of social support. It contains four
domains to assess perceived availability of social support, including (1) emotional/
informational support, (2) tangible support, (3) positive social interaction and (4)
affectionate support
Subjects will be asked about the ease of completion for both the Friendship Scale and
the (MOS-SSS), by ranking the level of difficulty from “very easy to complete” to “very
hard to complete”

Qualitative Interview
Although it is preferable for subjects to be interviewed prior to completing any of the instruments,
in order to minimize bias that the instruments may impose, it is likely that subject interviews may
take place after respective subjects complete the surveys. Approximately 30 subjects will be
interviewed. Measurement generation will begin by collecting a range of patient perspectives
regarding feelings of social isolation and social support. Interviews will be facilitated by a semistructured interview guide, allowing opportunity for interviewees to share additional experiences
not addressed by the questions.
Location/Duration/Approach of Individual qualitative interviews The investigator will be the
sole conductor of the individual semi structured qualitative interviews; following a prepared topic
guide. It is anticipated that 30 subject interviews will allow for saturation of the topics of social
isolation and social support. Interviews will be audiotaped at the time of conduct. Interviews will
be conducted in person, via telephone conference or virtually (ie, Skype®), depending upon
logistics.
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Following completion of the subject interviews, all information will be transcribed and uploaded
into nVivo for further qualitative analysis.
As we are requesting a waiver of signed consent, this Information for Survey Participants Statement of Research document will be provided and it will describe the goals of this study and
will contain all other required elements of consent. It also notes what will be asked, how long it
should take to complete, assurance of confidentiality, and that remuneration - in the form of entry
into a drawing for an Apple iPad – is optional for participants. Participants will be informed that
consent to participate is implied by return of the completed survey.
b. Protection against Risk
Minimal risk is anticipated. In the event of an unexpected event as a result of participating in the
interviews, the participant will be instructed to contact the investigator. Based on the experience
of the PI, it is anticipated that the risk of AEs will be acceptably low. In the event of an AE, it will
be recorded and submitted to the IRB and PI according to institutional procedures. The PI and
PI’s doctoral advisor will review all AEs.
The Information for Survey Participants document assures confidentiality of all information
obtained during the study. In particular, confidentiality of subjects will be guarded by conducting
data collection (interviews and questionnaire instrument administration) in a private clinical
setting/location that will be secured by the investigator in advance of the planned meeting. The
confidential data will be deidentified for purposes of transcription and analysis. Each subject will
be assigned a unique participant code known only to the investigator and maintained in a locked
fashion. Breach of confidentiality may be considered an adverse event, and may be reported to
the IRB. Maximal efforts will be undertaken to ensure the safety of all participants. Participants
will be instructed on how to access the, PI or in the event of study-related questions. In the event
of study-related illness or injury, participants will be instructed on how to access health care.
Participants will be given a card with the investigator’s name and phone numbers to contact in the
event there is a problem.
All personal information, such as phone numbers or emails for follow up, will not be connected to
any data and will be discarded after interviews are complete and the Apple iPad is distributed.
Each subject will be assigned a unique study ID number for the purposes of linking a unique
person with a given set of data.
There are no social or legal risks associated with participation in the study. Confidentiality will be
maintained for all other collected data. The subject identification and enrollment log will be
treated as confidential and will be filed by the investigator in the study file. To ensure subject
confidentiality, no paper copies will be made. All reports and communications relating to the study
will identify subjects by assigned number. All electronic files will be protected via encryption, and
the password(s) to those files accessible to the investigator and the investigator’s doctoral advisor
only.
G. POTENTIAL BENEFITS OF THE PROPOSED RESEARCH TO THE SUBJECTS AND
OTHERS
There is no direct benefit of the research to the subject. However, the disclosures of the
participants will inform future measurement of perceptions of social isolation and other social
burdens not yet recognized or addressed by the scientific community. Measurement develops
empirical evidence to support intervention development and identify health disparities.
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H. IMPORTANCE OF THE KNOWLEDGE TO BE GAINED
This study will provide valuable information for the purposes of informing future studies designed
to investigate interventions that can ameliorate social isolation in individuals with Alpha-1
antitrypsin deficiency, sarcoidosis, and potentially other rare lung diseases. In addition, the
knowledge gained is important because these sample communities could be representative of the
needs of other rare disease populations
I. SUBJECT SAFETY AND MINIMIZING RISKS (Data and Safety Monitoring Plan)
N/A
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Running Head: Social Isolation and Social Support in Alpha-1 and Sarcoidosis

Table 8. Triangulation of quantitative and qualitative findings.
Domain

Social
Support
[as measured
by the
MOS-SSS
Total Score]

Quantitative
Instrument
Scores Overall
Population
63.8
(some lack of
support)

Quantitative
Instrument
Scores Alpha-1
Population
66.4
(some lack of
support)

Quantitative
Instrument
Scores:
Sarcoidosis
56.9
(more
pronounced lack
of support)

Qualitative Narratives:
Alpha-1

Qualitative Narratives: Sarcoidosis

“And my kids they are
not very sympathetic;
there is no real empathy
there from kids. They
know I have this
problem but they really
are not too interested or
involved.” [FS 4; MOSSSS 1.3]
• “I couldn’t be happier
with the Alpha-1
support system that is in
place. I have just
involved, I am going to
be involved in a study
in St. Louis for the
liver.”[FS 24; MOS:
96.1]
• “There is no support
group where I live. It’s
like two hours away. I
do have good support…
I do a lot of online.”[FS
18; MOS: 64.5]
• “I have good support

• “I am on the two Facebook pages… But to be
honest with you I try to stay off those
because I get depressed because there's
people in worse condition than I am”[FS:
23; MOS: 96.1
• “I am also a member of the Peer Support
Unit of Boston Police Department even
though I am retired, and we’ve got resources
there that I can call, contact you know I can
contact and call upon if I need support.”
”[FS: 23; MOS: 96.1]
• “I feel fortunate that I have that, and like I
said the biggest thing for me with the, was
the Facebook pages…social media can be a
good thing… just when I look at people that
are worse off than me I am like this really
isn’t for me” [FS: 23; MOS: 96.1]
• “I have some friends on Facebook … I can
talk freely to and I feel– … they tend to be
judgmental or they tend to just, I am sicker
than you and I am this, there is a lot of “I”
going around, I don’t like a lot of the groups
on Facebook, so I have five or six people
that I talk to regularly.”[FS: 15; MOS:
35.5]

•

Table 8. Triangulation of quantitative and qualitative findings.
Domain

Quantitative
Instrument
Scores Overall
Population

Quantitative
Instrument
Scores Alpha-1
Population

Quantitative
Instrument
Scores:
Sarcoidosis

Qualitative Narratives:
Alpha-1

•

Social
Isolation
[as measured
by the
Friendship
Scale]

16.3
(some social
isolation or
some social
support)

17.0
(some social
isolation or
some social
support)

14.5
(isolated or with
a low level of
social support)
** findings
between alpha-1

•

good support – the only
thing that I miss is
being able to have
somebody go, yeah, I
totally understand, but
much you may know
me the side of the other
thing.”{FS 18; MOS:
64.47]
“I’m on Facebook and I
have got hundreds of
friends on Facebook
and they all seem to
know that I have this
double thing going on.
I don’t care, I’m open
about it. It’s how I get
my support”[FS 17;
MOS: 64.47]
“I have a very small
core support group of
family and friends that
know my condition that
I feel comfortable being
around because they
know why I am slow,

Qualitative Narratives: Sarcoidosis

•

•

•

and there are only five people in my support
group and in January nobody came to my
meeting, I had a guest speaker, so totally
embarrassed that nobody came…I want to
just to reach out to everybody and like, are
you going to come if I have a meeting
because I don’t want to come and sit there
by myself for an hour.” [FS: 15; MOS:
35.5]
“..The XX site has gotten a pretty unhealthy
lately. So we pulled off about eight months
ago and said let's create the little Facebook
group and private group. This little tight
group is seven of us who always seem to
respond to each other’s post and always
seem to be very supportive of each other just
had to make a little offset group…” [FS: 15;
MOS: 35.5]
“…. support is very important, you do feel
very isolated with this disease..there is not a
lot out there. There is not a lot of medical
information out there.” [FS: 15; MOS:
35.5]
“I have some [friends] that talk to me on
Facebook; for the most part my friends have
91

Table 8. Triangulation of quantitative and qualitative findings.
Domain

Quantitative
Instrument
Scores Overall
Population

Quantitative
Instrument
Scores Alpha-1
Population

Quantitative
Instrument
Scores:
Sarcoidosis
population and
sarcoidosis
population were
statistically
significant at
p=0.009

Qualitative Narratives:
Alpha-1

•

•

•

why I get short of
breath. But mostly I
don’t have a social life
anymore”[FS: 14.4;
MOS: 81.6]
“I still go as much as I
feel that I can, I still
isolate myself more
than average person
probably that’s much
better than what I want
to do.”[FS 9; MOS:
13.2]
“Let me tell you what I
call this disease. I
called it the lonely
disease and that
probably sums it up in a
nutshell.”
“Mine (life) has been
impacted negatively
very much and I know
and it gets a little bit or
it gets more isolated
you know as time goes
by”. [FS 17: MOS:

Qualitative Narratives: Sarcoidosis

•

•

•

gone; I don’t have the common things that
we used to working together.” [FS 7; MOS
11.8]
“I didn’t talk to people for months on end
because it was just so depleting to even
have a talk”[FS 20; MOS: 89.5]
“I’m rarely out instead of rarely in the
house, now I’m rarely out of the house. I am
very much -- I almost feel hermitish,
because I know that if I -- even if I do feel
good and I go and do one of those things, I
will have trouble for the next two days after
that with pain”[FS 15; MOS:61.8]
Mostly there are days that are so lonely and
so – just – that I have actually said to my
physician I promise you I cannot live the
rest of my life this way and I meant every
ounce of the word.[FS: 20; 96.1]
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Table 8. Triangulation of quantitative and qualitative findings.
Domain

Quantitative
Instrument
Scores Overall
Population

Quantitative
Instrument
Scores Alpha-1
Population

Quantitative
Instrument
Scores:
Sarcoidosis

Qualitative Narratives:
Alpha-1

Qualitative Narratives: Sarcoidosis

64.5]
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